BLOOD CANCER UNITED INC: Form 990, tax year 2016

View the entire original 990 at ProPublica ↗

Organization
BLOOD CANCER UNITED INC (EIN 13-5644916)
Tax period
2016-07-01 to 2017-06-30
Filed
2018-02-23
IRS object ID
201840549349300244
Schema version
2016v3.1
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Return2018-02-23T14:52:22-05:00ReturnTs
Tax Period End2017-06-30TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

FieldValueIRS element (for citing)
Preparer Firm EIN135565207PreparerFirmEIN

Preparer Firm Name PreparerFirmName

FieldValueIRS element (for citing)
Business Name Line1KPMG LLPBusinessNameLine1Txt

Preparer US Address PreparerUSAddress

FieldValueIRS element (for citing)
Address Line1345 PARK AVENUEAddressLine1Txt
CityNEW YORKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP101540102ZIPCd
FieldValueIRS element (for citing)
Return Type990ReturnTypeCd
Tax Period Begin2016-07-01TaxPeriodBeginDt

Filer Filer

FieldValueIRS element (for citing)
EIN135644916EIN

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1THE LEUKEMIA & LYMPHOMA SOCIETYINCBusinessNameLine1Txt
FieldValueIRS element (for citing)
Business Name ControlLEUKBusinessNameControlTxt
Phone9149495213PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line13 INTERNATIONAL DRIVEAddressLine1Txt
CityRYE BROOKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10573ZIPCd

Business Officer BusinessOfficerGrp

FieldValueIRS element (for citing)
PersonROSEMARIE A LOFFREDOPersonNm
Person TitleEVP - CFOPersonTitleTxt
Phone9148218908PhoneNum
Signature2018-02-23SignatureDt
Discuss With Paid PreparerYes (true)DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

FieldValueIRS element (for citing)
Preparer PersonDAVID M HIGHFILLPreparerPersonNm
PTINP01517891PTIN
Phone2127589700PhoneNum
Preparation2018-02-23PreparationDt

Filing Security Information FilingSecurityInformation

FieldValueIRS element (for citing)
At Submission Creation Device Id5169B9C1869B4BD13DE3B279716107AD2954B893AtSubmissionCreationDeviceId
At Submission Filing Device Id5169B9C1869B4BD13DE3B279716107AD2954B893AtSubmissionFilingDeviceId
FieldValueIRS element (for citing)
Tax2016TaxYr
Build TS2021-01-29 14:40:06ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Principal OfficerLOUIS J DEGENNAROPrincipalOfficerNm

US Address USAddress

FieldValueIRS element (for citing)
Address Line13 INTERNATIONAL DRIVE SUITE 200AddressLine1Txt
CityRYE BROOKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10573ZIPCd
FieldValueIRS element (for citing)
Gross Receipts$454,488,208GrossReceiptsAmt
Group Return For AffiliatesfalseGroupReturnForAffiliatesInd
Organization501c3Yes (X)Organization501c3Ind
Website AddressWWW.LLS.ORGWebsiteAddressTxt
Type Of Organization CorpYes (X)TypeOfOrganizationCorpInd
Formation1949FormationYr
Legal Domicile StateNYLegalDomicileStateCd
Activity Or MissionOUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.ActivityOrMissionDesc
Voting Members Governing Body27VotingMembersGoverningBodyCnt
Voting Members Independent27VotingMembersIndependentCnt
Total Employee1302TotalEmployeeCnt
Total Volunteers3000000TotalVolunteersCnt
Total Gross UBI$0TotalGrossUBIAmt
PY Contributions Grants$285,638,088PYContributionsGrantsAmt
CY Contributions Grants$314,912,814CYContributionsGrantsAmt
CY Program Service Revenue$3,847,456CYProgramServiceRevenueAmt
PY Investment Income-$6,187,940PYInvestmentIncomeAmt
CY Investment Income$1,121,864CYInvestmentIncomeAmt
PY Other Revenue-$7,722,874PYOtherRevenueAmt
CY Other Revenue$25,416,466CYOtherRevenueAmt
PY Total Revenue$271,727,274PYTotalRevenueAmt
CY Total Revenue$345,298,600CYTotalRevenueAmt
PY Grants And Similar Paid$88,538,361PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid$122,873,965CYGrantsAndSimilarPaidAmt
CY Benefits Paid To Members$0CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid$87,185,045PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid$97,808,057CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns$4,059,876PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns$4,046,893CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense$41,120,267CYTotalFundraisingExpenseAmt
PY Other Expenses$74,986,029PYOtherExpensesAmt
CY Other Expenses$90,757,098CYOtherExpensesAmt
PY Total Expenses$254,769,311PYTotalExpensesAmt
CY Total Expenses$315,486,013CYTotalExpensesAmt
PY Revenues Less Expenses$16,957,963PYRevenuesLessExpensesAmt
CY Revenues Less Expenses$29,812,587CYRevenuesLessExpensesAmt
Total Assets BOY$217,192,867TotalAssetsBOYAmt
Total Assets EOY$272,265,949TotalAssetsEOYAmt
Total Liabilities BOY$99,112,566TotalLiabilitiesBOYAmt
Total Liabilities EOY$119,978,224TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY$118,080,301NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY$152,287,725NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part IIIYes (X)InfoInScheduleOPartIIIInd
MissionOUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.MissionDesc
Significant New Program SrvcfalseSignificantNewProgramSrvcInd
Significant ChangefalseSignificantChangeInd
Expense$64,184,207ExpenseAmt
Grant$53,786,718GrantAmt
Revenue$29,167,652RevenueAmt
DescA) RESEARCH PROGRAMS: WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVE OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. TO DATE, LLS HAS INVESTED OVER 1.2 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. (CONTINUED ON SCHEDULE O) WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2017, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 50 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, AND, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGAINST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2017, FOR THE SIXTH YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOLENT LYMPHOMA PATIENTS - DEFINE GENETIC/MOLECULAR PREDISPOSITIDesc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

FieldValueIRS element (for citing)
Expense$121,459,664ExpenseAmt
Grant$74,671,557GrantAmt
DescB) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1.29 MILLION PEOPLE ACROSS THE UNITED STATES (US) CURRENTLY BATTLE LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS AN ARRAY OF FREE, COMPREHENSIVE RESOURCES TO BLOOD CANCER PATIENTS, CAREGIVERS, FAMILIES AND FRIENDS OF PATIENTS, ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION; PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. (CONTINUED ON SCHEDULE O) SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PRINT PUBLICATIONS AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES DISEASE AND SUPPORT BOOKLETS AND FACT SHEETS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. EACH YEAR, LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. - 632,829 FREE PRINTED DISEASE AND SUPPORT BOOKLETS AND 7,191 DISEASE- FOCUSED FACT SHEETS WERE ORDERED IN 2017. ADDITIONALLY, THERE WERE 86,615 PAGE VIEWS OF THESE BOOKLETS AND FACT SHEETS ON THE LLS WEBSITE. FINANCIAL ASSISTANCE IN 2017, A COMBINED 74,188,838 WAS DISBURSED TO PATIENTS THROUGH THE CO- PAY ASSISTANCE PROGRAMS (72,968,508) AND THE LLS NATIONAL PATIENT TRAVEL ASSISTANCE PROGRAM, (1,181,500), AND LLS FINANCIAL ASSISTANCE PROGRAM (38,830). CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2017, 72,968,508 WAS PROVIDED TO PATIENTS THROUGH THE LLS CO-PAY ASSISTANCE PROGRAM. - 31,026 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2017. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM THE SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS WITH TRAVEL AND LODGING EXPENSES RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. TRAVEL ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY. IN 2017, 1,181,500 WAS PROVIDED TO PATIENTS THROUGH THE LLS SUSAN LANG TRAVEL PROGRAM 2,363 PATIENTS RECEIVED LLS TRAVEL ASSISTANCE IN 2017. FINANCIAL ASSISTANCE PROGRAM FOR CML PATIENTS (PCR PROGRAM) THE FINANCIAL ASSISTANCE PROGRAM FOR CML PATIENTS SUPPORTS QUALIFYING PATIENTS WITH OUT OF POCKET EXPENSES RELATED TO THEIR ROUTINE POLYMERASE CHAIN REACTION (PCR) TESTING. IN 2017, 38,830 WAS PROVIDED TO PATIENTS THROUGH THE PCR PROGRAM. 85 PATIENTS RECEIVED LLS PCR ASSISTANCE IN 2017. COMMUNITY PROGRAMS SERVICES ARE PROVIDED IN COMMUNITIES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS BY PATIENT ACCESS STAFF AND TRAINED VOLUNTEERS WHO HAVE SPECIFIC SUPPORT AND OUTREACH ROLES. STAFF ARE HEALTHCARE AND ALLIED HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING, PUBLIC HEALTH OR SOCIAL WORK; VOLUNTEERS ARE TYPICALLY PATIENTS OR CAREGIVERS WHO UNDERGO RIGOROUS BACKGROUND CHECKS AND TRAINING. STAFF AND VOLUNTEERS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS, AND PROVIDE COMMUNITY-BASED OUTREACH, EDUCATION, AND SUPPORT IN A VARIETY OF FORMS. REGIONAL BLOOD CANCER CONFERENCES: LLS WORKS TO ELEVATE OUR VISIBILITY IN COMMUNITIES WE SERVE BY HOSTING LARGER-SCALE CONFERENCES, GEARED FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. THESE EVENTS ARE A CATALYST FOR BRINGING MANY DEDICATED PEOPLE TOGETHER TO FOCUS ON BLOOD CANCER AWARENESS, INFORMATION AND THE LATEST ADVANCES IN MEDICAL SCIENCE. THEY ARE DESIGNED FOR PATIENTS AND CAREGIVERS BUT ARE ATTENDED BY SOME LOCAL HEALTHCARE PROFESSIONALS (NURSES AND SOCIAL WORKERS) AS WELL. IN 2017, 106 BCC CONFERENCES WERE HELD WITH 3,352 ATTENDEES. LLS COMMUNITY THE ONLINE "LLS COMMUNITY" WAS LAUNCHED ON FEBRUARY 1, 2016. IT WAS DESIGNED TO PROVIDE A WAY FOR PATIENTS AND CAREGIVERS TO: 1) BECOME PART OF A SOCIAL NETWORK TO CONNECT WITH PATIENTS AND CAREGIVERS IN SIMILAR SITUATIONS AND BECOME EMPOWERED; 2) PROVIDE INFORMATION ABOUT ONESELF AND ONE'S DISEASE, TO BECOME PART OF THE RESEARCH TO CURE BLOOD CANCERS; AND 3) GAIN THE LATEST INFORMATION ABOUT ONE'S DISEASE, LEARN ABOUT SURVIVORSHIP ISSUES, AND ABOUT CLINICAL TRIALS. BY THE END OF FY 2017, THERE WERE APPROXIMATELY 6,000 COMMUNITY MEMBERS AND 44,000 RESPONSES TO THE "QUESTIONS OF THE DAY," AS WELL AS CLOSE TO 13,500 COMMENTS POSTED BY USERS. FAMILY SUPPORT GROUPS: THROUGHOUT THE US, IN 2017, LLS SUPPORTED OR HOSTED 135 FAMILY SUPPORT GROUPS FOR PATIENTS AND THEIR FAMILIES. GROUPS ARE GUIDED BY ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. LLS SUPPORT GROUPS ARE THE PERFECT PLACE TO TALK WITH OTHER PEOPLE AFFECTED BY BLOOD CANCERS, INCLUDING PATIENTS, FAMILY MEMBERS AND CAREGIVERS. THE GROUPS PROVIDE MUTUAL SUPPORT AND OFFER THE OPPORTUNITY TO DISCUSS ANXIETIES AND CONCERNS WITH OTHERS WHO SHARE THE SAME EXPERIENCES. THIS SHARING STRENGTHENS THE FAMILY BOND AND ENHANCES EVERYONE'S ABILITY TO COPE WITH CANCER. IN ADDITION, LLS HOSTED 7 ONLINE CHAT GROUPS - I.E., VIRTUAL SUPPORT GROUPS - THAT ARE PROFESSIONALLY MODERATED. IN FY 2017, 3,506 INDIVIDUALS PARTICIPATED IN THESE CHATS. PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM: FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT- VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS; REFERRAL IS ALSO PROVIDED BY LLS'S INFORMATION RESOURCE CENTER. -OVER 1,100 FIRST CONNECTIONS WERE MADE ACROSS THE US IN FY 2017.Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

FieldValueIRS element (for citing)
Expense$41,862,025ExpenseAmt
DescC) PUBLIC HEALTH EDUCATION: INFORMATION AND EDUCATION. PAYING FOR MEDICAL CARE, MAKING TREATMENT CHOICES, COMMUNICATING WITH HEALTHCARE PROVIDERS, FAMILY MEMBERS AND FRIENDS-THESE ARE SOME OF THE STRESSES THAT COME WITH A CANCER DIAGNOSIS. LLS'S INFORMATION SPECIALISTS ARE MASTER'S LEVEL ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. (CONTINUED ON SCHEDULE O) INFORMATION SPECIALISTS ALSO CONDUCT CLINICAL-TRIAL SEARCHES TO HELP PATIENTS WORK WITH THEIR DOCTORS TO FIND OUT ABOUT SPECIFIC CLINICAL TRIALS. THE INFORMATION RESOURCE CENTER ALSO HAS AN EXPANDING IN-DEPTH CLINICAL TRIAL NAVIGATION SERVICE. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. IN FY 2017: - 17,800 INQUIRIES WERE MADE TO OUR INFORMATION SPECIALISTS. - 10,632 HOUSEHOLDS RECEIVED INFORMATION AND/OR SUPPORT FROM INFORMATION SPECIALISTS VIA EMAILS, PHONE, AND ANSWER CHATS. -339 PATIENTS WORKED WITH A CLINICAL TRIAL NAVIGATOR TO RECEIVE COMPREHENSIVE ASSISTANCE WITH CLINICAL TRIAL ENROLLMENT; OVER 60% OF THESE PATIENTS ENROLLED ON A CLINICAL TRIAL. THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, DISCUSSION BOARDS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL- TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. INFORMATIONAL MATERIALS ARE AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. MANY DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS ADDITIONALLY, LLS ALSO SPONSORS TELEPHONE- WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. ALSO AVAILABLE THROUGH THE LLS WEBSITE ARE VIRTUAL LECTURES AND VIDEOS FEATURING DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. IN FY 2017: -LLS PROVIDED 10 LIVE NATIONAL TELEPHONE-WEB EDUCATION PROGRAMS, WITH 4,605 PARTICIPANTS -THERE WERE 21,766 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, 29,453 VIEWS OF VIDEOS.Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp

FieldValueIRS element (for citing)
Expense$20,136,094ExpenseAmt
DescD) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. IN FY 2017: -LLS PROVIDED 5 CME/CE-GRANTING PERSON EDUCATIONAL PROGRAMS ("ROUNDS"), WITH 1,468 HEALTHCARE PROFESSIONAL IN ATTENDANCE. -THERE WAS 1 NATIONAL TELEPHONE-WEB EDUCATION PROGRAM FOCUSED ON AML FOR PROFESSIONALS WITH 479 PARTICIPANTS. -THERE WERE 9,656 VIEWS OF OUR ONLINE VIRTUAL LECTURES FOR PROFESSIONALS AND 2,904 VIEWS OF OUR ONLINE VIDEOS FOR PROFESSIONALS.Desc
FieldValueIRS element (for citing)
Total Other Prog Srvc Expense$20,136,094TotalOtherProgSrvcExpenseAmt
Total Program Service Expenses$247,641,990TotalProgramServiceExpensesAmt
Described In Section501c3Yes (true)DescribedInSection501c3Ind
Schedule B RequiredYes (true)ScheduleBRequiredInd
Political Campaign ActyfalsePoliticalCampaignActyInd
Lobbying ActivitiesYes (true)LobbyingActivitiesInd
Subject To Proxy TaxfalseSubjectToProxyTaxInd
Donor Advised FundfalseDonorAdvisedFundInd
Conservation EasementsfalseConservationEasementsInd
Collections Of ArtYes (true)CollectionsOfArtInd
Credit CounselingfalseCreditCounselingInd
Temp Or Permanent EndowmentsYes (true)TempOrPermanentEndowmentsInd
Report Land Building EquipmentYes (true)ReportLandBuildingEquipmentInd
Report Investments Other SecfalseReportInvestmentsOtherSecInd
Report Program Related InvstfalseReportProgramRelatedInvstInd
Report Other AssetsfalseReportOtherAssetsInd
Report Other LiabilitiesfalseReportOtherLiabilitiesInd
Include FIN48 FootnoteYes (true)IncludeFIN48FootnoteInd
Independent Audit Fincl StmtfalseIndependentAuditFinclStmtInd
Consolidated Audit Fincl StmtYes (true)ConsolidatedAuditFinclStmtInd
School OperatingfalseSchoolOperatingInd
Foreign OfficeYes (true)ForeignOfficeInd
Foreign ActivitiesYes (true)ForeignActivitiesInd
More Than5000 K To OrgYes (true)MoreThan5000KToOrgInd
More Than5000 K To IndividualsfalseMoreThan5000KToIndividualsInd
Professional FundraisingYes (true)ProfessionalFundraisingInd
Fundraising ActivitiesYes (true)FundraisingActivitiesInd
Gaming ActivitiesYes (true)GamingActivitiesInd
Operate HospitalfalseOperateHospitalInd
Grants To OrganizationsYes (true)GrantsToOrganizationsInd
Grants To IndividualsYes (true)GrantsToIndividualsInd
Schedule J RequiredYes (true)ScheduleJRequiredInd
Tax Exempt BondsfalseTaxExemptBondsInd
Engaged In Excess Benefit TransfalseEngagedInExcessBenefitTransInd
PY Excess Benefit TransfalsePYExcessBenefitTransInd
Loan OutstandingfalseLoanOutstandingInd
Grant To Related PersonfalseGrantToRelatedPersonInd
Business Rln With Org MemfalseBusinessRlnWithOrgMemInd
Business Rln With Fam MemfalseBusinessRlnWithFamMemInd
Business Rln With Officer EntfalseBusinessRlnWithOfficerEntInd
Deductible Non Cash ContriYes (true)DeductibleNonCashContriInd
Deductible Art ContributionfalseDeductibleArtContributionInd
Terminate OperationsfalseTerminateOperationsInd
Partial LiquidationfalsePartialLiquidationInd
Disregarded EntityYes (true)DisregardedEntityInd
Related EntityYes (true)RelatedEntityInd
Related Organization Ctrl EntYes (true)RelatedOrganizationCtrlEntInd
Transaction With Control EntYes (true)TransactionWithControlEntInd
Trnsfr Exmpt Non Chrtbl Rltd OrgfalseTrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted PrtshpfalseActivitiesConductedPrtshpInd
Schedule O RequiredYes (true)ScheduleORequiredInd
IRP Document598IRPDocumentCnt
IRP Document W2 G4IRPDocumentW2GCnt
Backup Wthld ComplianceYes (true)BackupWthldComplianceInd
Employee1302EmployeeCnt
Employment Tax Returns FiledYes (true)EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over LimitfalseUnrelatedBusIncmOverLimitInd
Foreign Financial AccountYes (true)ForeignFinancialAccountInd
Foreign CountryCAForeignCountryCd
Prohibited Tax Shelter TransfalseProhibitedTaxShelterTransInd
Taxable Party NotificationfalseTaxablePartyNotificationInd
Nondeductible ContributionsfalseNondeductibleContributionsInd
Quid Pro Quo ContributionsYes (true)QuidProQuoContributionsInd
Quid Pro Quo Contri DisclYes (true)QuidProQuoContriDisclInd
Form8282 Property Disposed OffalseForm8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft CntrctfalseRcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft CntrctfalsePayPremiumsPrsnlBnftCntrctInd
Indoor Tanning ServicesfalseIndoorTanningServicesInd
Info In Schedule O Part VIYes (X)InfoInScheduleOPartVIInd
Governing Body Voting Members27GoverningBodyVotingMembersCnt
Independent Voting Member27IndependentVotingMemberCnt
Family Or Business RlnfalseFamilyOrBusinessRlnInd
Delegation Of Mgmt DutiesfalseDelegationOfMgmtDutiesInd
Change To Org DocumentsfalseChangeToOrgDocumentsInd
Material Diversion Or MisusefalseMaterialDiversionOrMisuseInd
Members Or StockholdersYes (true)MembersOrStockholdersInd
Election Of Board MembersYes (true)ElectionOfBoardMembersInd
Decisions Subject To ApprovaYes (true)DecisionsSubjectToApprovaInd
Minutes Of Governing BodyYes (true)MinutesOfGoverningBodyInd
Minutes Of CommitteesYes (true)MinutesOfCommitteesInd
Officer Mailing AddressfalseOfficerMailingAddressInd
Local ChaptersYes (true)LocalChaptersInd
Policies Reference ChaptersYes (true)PoliciesReferenceChaptersInd
Form990 Provided To Gvrn BodyYes (true)Form990ProvidedToGvrnBodyInd
Conflict Of Interest PolicyYes (true)ConflictOfInterestPolicyInd
Annual Disclosure Covered PrsnYes (true)AnnualDisclosureCoveredPrsnInd
Regular Monitoring EnfrcYes (true)RegularMonitoringEnfrcInd
Whistleblower PolicyYes (true)WhistleblowerPolicyInd
Document Retention PolicyYes (true)DocumentRetentionPolicyInd
Compensation Process CEOYes (true)CompensationProcessCEOInd
Compensation Process OtherYes (true)CompensationProcessOtherInd
Investment In Joint VenturefalseInvestmentInJointVentureInd
States Where Copy Of Return Is FldAKStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldALStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldARStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldAZStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCOStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCTStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldDEStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldDCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldFLStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldGAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldHIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldIDStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldILStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldINStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKSStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldLAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMDStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMEStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMOStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMSStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNHStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNJStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNMStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNEStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldOHStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldOKStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldORStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldPAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldPRStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldRIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldSCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldTNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldUTStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldVAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWVStatesWhereCopyOfReturnIsFldCd
Own WebsiteYes (X)OwnWebsiteInd
Upon RequestYes (X)UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

FieldValueIRS element (for citing)
PersonROSEMARIE A LOFFREDOPersonNm
Phone9149495213PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line13 INTERNATIONAL DRIVEAddressLine1Txt
CityRYE BROOKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10573ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (39 entries)

TitleTitleTxtAverage Hours Per WeekAverageHoursPerWeekRtAverage Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRtOfficerOfficerIndReportable Comp From OrgReportableCompFromOrgAmtReportable Comp From Rltd OrgReportableCompFromRltdOrgAmtOther CompensationOtherCompensationAmtKey EmployeeKeyEmployeeIndHighest Compensated EmployeeHighestCompensatedEmployeeIndFormer Ofcr Director TrusteeFormerOfcrDirectorTrusteeIndIndividual Trustee Or DirectorIndividualTrusteeOrDirectorInd
LOUIS J DEGENNARO
PRESIDENT &40.001.00Yes (X)$522,261$0$101,298
ROSEMARIE A LOFFREDO
EVP - CFO40.001.00Yes (X)$393,691$0$22,219
GORDON MILLER JR
SVP FINANCE40.005.00Yes (X)$254,734$0$40,974
MARK ROITHMAYR - TERM 12312016
EVP CHIEF RE40.00$412,015$0$39,075Yes (X)
ANDREW S COCCARI
EVP CHIEF PR40.00$353,754$0$30,120Yes (X)
ALICE O'ROURKE
EVP CHIEF DE40.00$292,097$0$28,864Yes (X)
LEE M GREENBERGER
SVP CHIEF SC40.00$305,682$0$38,692Yes (X)
PAULETTE DAMIANO - TERM 6302016
VP ORG DEV &40.00$319,566$0$19,981Yes (X)
COKER POWELL
SVP, LTN CAM40.00$239,284$0$27,077Yes (X)
DEBORAH MATZ
SVP, LEGAL A40.00$231,541$0$29,556Yes (X)
MICHELE PRZYPYSZNY - TERM 7212016
EXECUTIVE DI40.00$245,733$0$12,952Yes (X)
GEORGE J OMIROS-TERM APR15
EVP-CHIEF CA$111,126$0$0Yes (X)
PETER B BROCK
CHAIR6.002.00Yes (X)$0$0$0Yes (X)
JORGE L BENITEZ
VICE CHAIR4.002.00Yes (X)$0$0$0Yes (X)
RALPH E LAWSON
SECRETARY/TR4.002.00Yes (X)$0$0$0Yes (X)
RAANAN HOROWITZ
AT LARGE4.002.00Yes (X)$0$0$0Yes (X)
JAMES A BECK
BOD MEMBER4.00$0$0$0Yes (X)
WILLIAM G BEHNKE
BOD MEMBER4.00$0$0$0Yes (X)
A DANA CALLOW JR
BOD MEMBER4.00$0$0$0Yes (X)
RENZO CANETTA
BOD MEMBER4.00$0$0$0Yes (X)
SCOTT A CARROLL
BOD MEMBER4.00$0$0$0Yes (X)
ELIZABETH J CLARK PHD
BOD MEMBER4.00$0$0$0Yes (X)
WILLIAM S DALTON PHD
BOD MEMBER4.00$0$0$0Yes (X)
BERNARD H GARIL
BOD MEMBER4.00$0$0$0Yes (X)
FRANCIE HELLER
BOD MEMBER4.00$0$0$0Yes (X)
RICHARD M JEANNERET
BOD MEMBER4.00$0$0$0Yes (X)
JOSEPH B KELLEY
BOD MEMBER4.00$0$0$0Yes (X)
MICHELLE LE BEAU PHD
BOD MEMBER4.00$0$0$0Yes (X)
CONNIE L LINDSEY
BOD MEMBER4.00$0$0$0Yes (X)
KATHLEEN MERIWETHER
BOD MEMBER4.00$0$0$0Yes (X)
TED MOROZ
BOD MEMBER4.00$0$0$0Yes (X)
DONALD PROCTOR
BOD MEMBER4.00$0$0$0Yes (X)
STEVEN T ROSEN
BOD MEMBER4.00$0$0$0Yes (X)
KENNETH M SCHWARTZ
BOD MEMBER4.00$0$0$0Yes (X)
BART SICHEL
BOD MEMBER4.00$0$0$0Yes (X)
FRANK O SMITH
BOD MEMBER4.00$0$0$0Yes (X)
KATHRYN C VECELLIO
BOD MEMBER4.00$0$0$0Yes (X)
LOUISE G WARNER
BOD MEMBER4.00$0$0$0Yes (X)
KEITH S WHITE
BOD MEMBER4.00$0$0$0Yes (X)
FieldValueIRS element (for citing)
Total Reportable Comp From Org$3,681,484TotalReportableCompFromOrgAmt
Total Other Compensation$390,808TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K164IndivRcvdGreaterThan100KCnt
Former Ofcr Employees ListedYes (true)FormerOfcrEmployeesListedInd
Total Comp Greater Than150 KYes (true)TotalCompGreaterThan150KInd
Compensation From Other SrcsfalseCompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1TxtCityContractorAddress/USAddress/CityNmState AbbreviationContractorAddress/USAddress/StateAbbreviationCdZIPContractorAddress/USAddress/ZIPCdServicesServicesDescCompensationCompensationAmt
RESOURCE ONE
2900 EAST APACHE STREETTULSAOK74110DIRECT MARKETIN$4,807,955
PATIENT ADVOCACY FOUNDATION
421 BUTLER FARM RDHAMPTONVA23666PAT ASSIST PROC$4,595,472
INC RESEARCH LLC
75 REMITTANCE DRIVE SUITE 3160CHICAGOIL606753160CLINICAL TRIAL$3,162,386
OLIVER STAFFING INC
350 LEXINGTON AV SUITE 401NEW YORKNY10016TEMP STAFFING$3,133,056
NORTHGATE DIGITAL CORPORATION
301 SOUTH STATE STREET SUITE N-200NEWTOWNPA189401956SOFTWARE DEVELO$1,834,796
FieldValueIRS element (for citing)
Cntrct Rcvd Greater Than100 K152CntrctRcvdGreaterThan100KCnt
Info In Schedule O Part VIIIYes (X)InfoInScheduleOPartVIIIInd
Federated Campaigns$1,485,588FederatedCampaignsAmt
Fundraising$164,610,688FundraisingAmt
All Other Contributions$148,816,538AllOtherContributionsAmt
Noncash Contributions$7,007,546NoncashContributionsAmt
Total Contributions$314,912,814TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp

FieldValueIRS element (for citing)
DescSERVICE REVENUEDesc
Business541900BusinessCd
Total Revenue Column$3,847,456TotalRevenueColumnAmt
Related Or Exempt Func Income$3,847,456RelatedOrExemptFuncIncomeAmt
FieldValueIRS element (for citing)
Total Program Service Revenue$3,847,456TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

FieldValueIRS element (for citing)
Total Revenue Column$2,791,064TotalRevenueColumnAmt
Exclusion$2,791,064ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$4,227,758TotalRevenueColumnAmt
Exclusion$4,227,758ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

FieldValueIRS element (for citing)
Securities$82,371,912SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

FieldValueIRS element (for citing)
Securities$78,606,889SecuritiesAmt
Other$5,434,223OtherAmt

Gain Or Loss GainOrLossGrp

FieldValueIRS element (for citing)
Securities$3,765,023SecuritiesAmt
Other-$5,434,223OtherAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

FieldValueIRS element (for citing)
Total Revenue Column-$1,669,200TotalRevenueColumnAmt
Exclusion-$1,669,200ExclusionAmt
FieldValueIRS element (for citing)
Fundraising Gross Income$19,972,736FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event$164,610,688ContriRptFundraisingEventAmt
Fundraising Direct Expenses$24,901,543FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

FieldValueIRS element (for citing)
Total Revenue Column-$4,928,807TotalRevenueColumnAmt
Exclusion-$4,928,807ExclusionAmt
FieldValueIRS element (for citing)
Gaming Gross Income$925,424GamingGrossIncomeAmt
Gaming Direct Expenses$246,953GamingDirectExpensesAmt

Net Income From Gaming NetIncomeFromGamingGrp

FieldValueIRS element (for citing)
Total Revenue Column$678,471TotalRevenueColumnAmt
Exclusion$678,471ExclusionAmt

Other Revenue Misc OtherRevenueMiscGrp (2 entries)

DescDescBusinessBusinessCdTotal Revenue ColumnTotalRevenueColumnAmtRelated Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmtExclusionExclusionAmt
TAP CONTRACTUAL RETURN541900$25,320,196$25,320,196
OTHER MISCELLANEOUS900099$118,848$118,848
FieldValueIRS element (for citing)
Other Revenue Total$25,439,044OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$345,298,600TotalRevenueColumnAmt
Related Or Exempt Func Income$29,167,652RelatedOrExemptFuncIncomeAmt
Exclusion$1,218,134ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

FieldValueIRS element (for citing)
Total$38,911,731TotalAmt
Program Services$38,911,731ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

FieldValueIRS element (for citing)
Total$74,671,557TotalAmt
Program Services$74,671,557ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

FieldValueIRS element (for citing)
Total$9,290,677TotalAmt
Program Services$9,290,677ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

FieldValueIRS element (for citing)
Total$2,121,068TotalAmt
Program Services$1,417,657ProgramServicesAmt
Management And General$336,932ManagementAndGeneralAmt
Fundraising$366,479FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

FieldValueIRS element (for citing)
Total$77,877,654TotalAmt
Program Services$52,114,364ProgramServicesAmt
Management And General$12,373,241ManagementAndGeneralAmt
Fundraising$13,390,049FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

FieldValueIRS element (for citing)
Total$2,067,484TotalAmt
Program Services$1,383,865ProgramServicesAmt
Management And General$325,194ManagementAndGeneralAmt
Fundraising$358,425FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

FieldValueIRS element (for citing)
Total$10,213,392TotalAmt
Program Services$6,836,306ProgramServicesAmt
Management And General$1,606,461ManagementAndGeneralAmt
Fundraising$1,770,625FundraisingAmt

Payroll Taxes PayrollTaxesGrp

FieldValueIRS element (for citing)
Total$5,528,459TotalAmt
Program Services$3,700,459ProgramServicesAmt
Management And General$869,569ManagementAndGeneralAmt
Fundraising$958,431FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

FieldValueIRS element (for citing)
Total$1,413,549TotalAmt
Program Services$971,712ProgramServicesAmt
Management And General$182,969ManagementAndGeneralAmt
Fundraising$258,868FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

FieldValueIRS element (for citing)
Total$445,582TotalAmt
Program Services$306,305ProgramServicesAmt
Management And General$57,676ManagementAndGeneralAmt
Fundraising$81,601FundraisingAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

FieldValueIRS element (for citing)
Total$1,264,751TotalAmt
Program Services$869,424ProgramServicesAmt
Management And General$163,709ManagementAndGeneralAmt
Fundraising$231,618FundraisingAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

FieldValueIRS element (for citing)
Total$4,046,893TotalAmt
Fundraising$4,046,893FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

FieldValueIRS element (for citing)
Total$387,928TotalAmt
Program Services$267,554ProgramServicesAmt
Management And General$58,189ManagementAndGeneralAmt
Fundraising$62,185FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

FieldValueIRS element (for citing)
Total$17,484,309TotalAmt
Program Services$12,019,186ProgramServicesAmt
Management And General$2,263,163ManagementAndGeneralAmt
Fundraising$3,201,960FundraisingAmt

Advertising AdvertisingGrp

FieldValueIRS element (for citing)
Total$6,397,782TotalAmt
Program Services$3,151,715ProgramServicesAmt
Management And General$758,878ManagementAndGeneralAmt
Fundraising$2,487,189FundraisingAmt

Office Expenses OfficeExpensesGrp

FieldValueIRS element (for citing)
Total$18,534,428TotalAmt
Program Services$9,774,722ProgramServicesAmt
Management And General$1,845,295ManagementAndGeneralAmt
Fundraising$6,914,411FundraisingAmt

Information Technology InformationTechnologyGrp

FieldValueIRS element (for citing)
Total$8,401,266TotalAmt
Program Services$5,775,257ProgramServicesAmt
Management And General$1,087,457ManagementAndGeneralAmt
Fundraising$1,538,552FundraisingAmt

Occupancy OccupancyGrp

FieldValueIRS element (for citing)
Total$8,949,426TotalAmt
Program Services$5,627,310ProgramServicesAmt
Management And General$1,212,500ManagementAndGeneralAmt
Fundraising$2,109,616FundraisingAmt

Travel TravelGrp

FieldValueIRS element (for citing)
Total$9,994,808TotalAmt
Program Services$6,723,444ProgramServicesAmt
Management And General$1,817,797ManagementAndGeneralAmt
Fundraising$1,453,567FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

FieldValueIRS element (for citing)
Total$7,480,169TotalAmt
Program Services$5,163,747ProgramServicesAmt
Management And General$1,115,810ManagementAndGeneralAmt
Fundraising$1,200,612FundraisingAmt

Insurance InsuranceGrp

FieldValueIRS element (for citing)
Total$669,265TotalAmt
Program Services$461,941ProgramServicesAmt
Management And General$100,082ManagementAndGeneralAmt
Fundraising$107,242FundraisingAmt

Other Expenses OtherExpensesGrp (2 entries)

DescDescTotalTotalAmtProgram ServicesProgramServicesAmtManagement And GeneralManagementAndGeneralAmtFundraisingFundraisingAmt
RESEARCH AND DEVELOPMENT$5,584,310$5,584,310
MISCELLANEOUS$3,749,525$2,618,747$548,834$581,944

Total Functional Expenses TotalFunctionalExpensesGrp

FieldValueIRS element (for citing)
Total$315,486,013TotalAmt
Program Services$247,641,990ProgramServicesAmt
Management And General$26,723,756ManagementAndGeneralAmt
Fundraising$41,120,267FundraisingAmt
FieldValueIRS element (for citing)
Joint CostsYes (X)JointCostsInd

Total Joint Costs TotalJointCostsGrp

FieldValueIRS element (for citing)
Total$13,095,492TotalAmt
Program Services$6,539,624ProgramServicesAmt
Fundraising$6,555,868FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

FieldValueIRS element (for citing)
BOY$14,966,805BOYAmt
EOY$37,250,666EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

FieldValueIRS element (for citing)
BOY$58,353,033BOYAmt
EOY$62,751,205EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

FieldValueIRS element (for citing)
BOY$16,707,733BOYAmt
EOY$16,228,169EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

FieldValueIRS element (for citing)
BOY$2,768,847BOYAmt
EOY$3,425,491EOYAmt
FieldValueIRS element (for citing)
Land Bldg Equip Cost Or Other Bss$41,166,184LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec$31,178,340LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

FieldValueIRS element (for citing)
BOY$16,736,701BOYAmt
EOY$9,987,844EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

FieldValueIRS element (for citing)
BOY$96,515,546BOYAmt
EOY$133,187,861EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

FieldValueIRS element (for citing)
BOY$11,144,202BOYAmt
EOY$9,434,713EOYAmt

Total Assets TotalAssetsGrp

FieldValueIRS element (for citing)
BOY$217,192,867BOYAmt
EOY$272,265,949EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

FieldValueIRS element (for citing)
BOY$14,820,632BOYAmt
EOY$24,296,564EOYAmt

Grants Payable GrantsPayableGrp

FieldValueIRS element (for citing)
BOY$71,699,343BOYAmt
EOY$82,120,581EOYAmt

Deferred Revenue DeferredRevenueGrp

FieldValueIRS element (for citing)
BOY$12,592,591BOYAmt
EOY$13,561,079EOYAmt

Total Liabilities TotalLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$99,112,566BOYAmt
EOY$119,978,224EOYAmt
FieldValueIRS element (for citing)
Organization Follows SFAS117Yes (X)OrganizationFollowsSFAS117Ind

Unrestricted Net Assets UnrestrictedNetAssetsGrp

FieldValueIRS element (for citing)
BOY$82,002,442BOYAmt
EOY$120,968,910EOYAmt

Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp

FieldValueIRS element (for citing)
BOY$32,998,850BOYAmt
EOY$28,432,696EOYAmt

Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp

FieldValueIRS element (for citing)
BOY$3,079,009BOYAmt
EOY$2,886,119EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$118,080,301BOYAmt
EOY$152,287,725EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$217,192,867BOYAmt
EOY$272,265,949EOYAmt
FieldValueIRS element (for citing)
Info In Schedule O Part XIYes (X)InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss$29,812,587ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst$4,662,977NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets-$268,140OtherChangesInNetAssetsAmt
Method Of Accounting AccrualYes (X)MethodOfAccountingAccrualInd
Accountant Compile Or ReviewYes (true)AccountantCompileOrReviewInd
FS AuditedYes (true)FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

FieldValueIRS element (for citing)
Consolidated Basis Fincl StmtYes (X)ConsolidatedBasisFinclStmtInd
FieldValueIRS element (for citing)
Audit CommitteeYes (true)AuditCommitteeInd
Federal Grant Audit RequiredfalseFederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Public Organization170Yes (X)PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$279,789,664CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$302,437,152CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$283,909,984CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$285,638,088CurrentTaxYearMinus1YearAmt
Current Tax Year$314,912,814CurrentTaxYearAmt
Total$1,466,687,702TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$279,789,664CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$302,437,152CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$283,909,984CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$285,638,088CurrentTaxYearMinus1YearAmt
Current Tax Year$314,912,814CurrentTaxYearAmt
Total$1,466,687,702TotalAmt
FieldValueIRS element (for citing)
Substantial Contributors Tot$245,762,639SubstantialContributorsTotAmt
Public Support Total170$1,220,925,063PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$2,260,636CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$1,203,865CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$1,891,412CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$1,565,846CurrentTaxYearMinus1YearAmt
Current Tax Year$7,018,822CurrentTaxYearAmt
Total$13,940,581TotalAmt

Other Income170 OtherIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$1,974,227CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$104,879CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$56,829CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$19,529CurrentTaxYearMinus1YearAmt
Current Tax Year$25,439,044CurrentTaxYearAmt
Total$27,594,508TotalAmt
FieldValueIRS element (for citing)
Total Support$1,508,222,791TotalSupportAmt
Gross Receipts Rltd Activities$117,717,676GrossReceiptsRltdActivitiesAmt
Public Support CY1700.80950PublicSupportCY170Pct
Public Support PY1700.84360PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170Yes (X)ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

FieldValueIRS element (for citing)
Form And Line ReferencePART II, LINE 10FormAndLineReferenceDesc
ExplanationGRANT TERM. & REFUND (YR 2012) 1,844,147 OTHER MISC. REVENUE (YR 2012-2016) 430,165 TAP CONTRACTUAL RETURN 25,320,196ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

FieldValueIRS element (for citing)
ContributorRESTRICTEDContributorNum

Contributor Business Name ContributorBusinessName

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor US Address ContributorUSAddress

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Total ContributionsRESTRICTEDTotalContributionsAmt

Schedule C IRS990ScheduleC

FieldValueIRS element (for citing)
VolunteersYes (true)VolunteersInd
Paid Staff Or ManagementYes (true)PaidStaffOrManagementInd
Media AdvertisementsfalseMediaAdvertisementsInd
Mailings MembersfalseMailingsMembersInd
Publications Or BroadcastYes (true)PublicationsOrBroadcastInd
Publications Or Broadcast$188,955PublicationsOrBroadcastAmt
Grants Other OrganizationsfalseGrantsOtherOrganizationsInd
Direct Contact LegislatorsYes (true)DirectContactLegislatorsInd
Direct Contact Legislators$207,888DirectContactLegislatorsAmt
Rallies DemonstrationsYes (true)RalliesDemonstrationsInd
Rallies Demonstrations$298,823RalliesDemonstrationsAmt
Other ActivitiesYes (true)OtherActivitiesInd
Other Activities$714,313OtherActivitiesAmt
Total Lobbying Expenditures$1,409,979TotalLobbyingExpendituresAmt
Not Described Section501c3falseNotDescribedSection501c3Ind

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE C, PART II-B, LINE 1LLS IS A MEMBER OF A NUMBER OF COALITIONS AND MEMBERSHIPS INCLUDING FRIENDS OF CANCER RESEARCH, ALLIANCE FOR A STRONGER FDA, ONE VOICE AGAINST CANCER, NATIONAL HEALTH COUNCIL, NORTH AMERICAN ASSOCIATION, AMERICAN CHILDHOOD CANCER ORGANIZATION, PUBLIC AFFAIRS COUNCIL, THE CANCER LEADERSHIP COUNCIL AND THE STATE ACCESS TO INNOVATIVE MEDICINES COALITION.
SCHEDULE C, PART IVLLS PARTNERS WITH A NUMBER OF LOBBYING FIRMS WHO WORK WITH OUR PUBLIC POLICY STAFF TO CARRY OUT OUR LOBBYING OBJECTIVES. LLS MOBILIZES PATIENT- ADVOCATES AND VOLUNTEERS TO ENGAGE WITH THEIR FEDERAL AND STATE LEGISLATORS THROUGH DIGITAL ADVOCACY - SENDING LETTERS; SHARING THEIR PERSONAL STORIES; SIGNING PETITIONS; AND ENCOURAGING THEIR LEGISLATORS TO SUPPORT LLS' POLICY PRIORITIES. IN CONJUNCTION WITH LLS EMPLOYEES, PATIENT-ADVOCATES ALSO VISIT THEIR LEGISLATORS IN THEIR LOCAL OFFICES, IN WASHINGTON, DC AND IN STATE CAPITOLS TO FURTHER LLS' POLICY AGENDA.

Schedule D IRS990ScheduleD

FieldValueIRS element (for citing)
Collection Used Pub ExhibitionYes (X)CollectionUsedPubExhibitionInd
Solicited Assets SalefalseSolicitedAssetsSaleInd

CY Endwmt Fund CYEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,027,967BeginningYearBalanceAmt
Contributions$5,200ContributionsAmt
Investment Earnings Or Losses$119,369InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$240,000GrantsOrScholarshipsAmt
Administrative Expenses-$15,159AdministrativeExpensesAmt
End Year Balance$5,897,377EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,115,645BeginningYearBalanceAmt
Contributions$45,095ContributionsAmt
Investment Earnings Or Losses$116,288InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$240,000GrantsOrScholarshipsAmt
Administrative Expenses-$9,060AdministrativeExpensesAmt
End Year Balance$6,027,967EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,122,698BeginningYearBalanceAmt
Investment Earnings Or Losses$218,549InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$221,499GrantsOrScholarshipsAmt
Administrative Expenses-$4,103AdministrativeExpensesAmt
End Year Balance$6,115,645EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,027,657BeginningYearBalanceAmt
Investment Earnings Or Losses$313,872InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$215,000GrantsOrScholarshipsAmt
Administrative Expenses-$3,831AdministrativeExpensesAmt
End Year Balance$6,122,698EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,000,186BeginningYearBalanceAmt
Investment Earnings Or Losses$482,520InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$450,000GrantsOrScholarshipsAmt
Administrative Expenses-$5,049AdministrativeExpensesAmt
End Year Balance$6,027,657EndYearBalanceAmt
FieldValueIRS element (for citing)
Prmnnt Endowment Balance EOY0.51000PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY0.49000TermEndowmentBalanceEOYPct
Endowments Held Unrelated OrgfalseEndowmentsHeldUnrelatedOrgInd
Endowments Held Related OrgfalseEndowmentsHeldRelatedOrgInd

Leasehold Improvements LeaseholdImprovementsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$1,567,984OtherCostOrOtherBasisAmt
Depreciation$856,968DepreciationAmt
Book Value$711,016BookValueAmt

Equipment EquipmentGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$35,693,636OtherCostOrOtherBasisAmt
Depreciation$27,252,511DepreciationAmt
Book Value$8,441,125BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$3,904,564OtherCostOrOtherBasisAmt
Depreciation$3,068,861DepreciationAmt
Book Value$835,703BookValueAmt
FieldValueIRS element (for citing)
Total Book Value Land Buildings$9,987,844TotalBookValueLandBuildingsAmt
Footnote TextYes (X)FootnoteTextInd
Total Rev Etc Audited Fincl Stmt$374,922,421TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst$4,662,977NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts$11,041,935DonatedServicesAndUseFcltsAmt
Other Revenue$8,699,483OtherRevenueAmt
Revenue Not Reported$24,404,395RevenueNotReportedAmt
Revenue Subtotal$350,518,026RevenueSubtotalAmt
Investment Expenses Not Incld$95,949InvestmentExpensesNotIncldAmt
Other Revenues Not Included-$5,315,375OtherRevenuesNotIncludedAmt
Revenue Not Reported Fincl Stmt-$5,219,426RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990$345,298,600TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt$337,468,337TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts$11,041,935DonatedServicesUseFcltsAmt
Other Expenses Included$10,852,338OtherExpensesIncludedAmt
Expenses Not Reported$21,894,273ExpensesNotReportedAmt
Expenses Subtotal$315,574,064ExpensesSubtotalAmt
Investment Expenses Not Incld2$95,949InvestmentExpensesNotIncld2Amt
Other Expenses Not Included-$184,000OtherExpensesNotIncludedAmt
Expenses Not Rpt Fincl Stmt-$88,051ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990$315,486,013TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (7 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE D, PAGE 2, PART III, LINE 4THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS.
SCHEDULE D, PAGE 2, PART V, LINE 4LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS.
SCHEDULE D, PAGE 3, PART XLLS RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE TAX POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. LLS DID NOT RECOGNIZE ANY UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2017 AND 2016.
SCHEDULE D, PAGE 4, PART XI, LINE 2DLLS CANADA REVENUE 8,524,695 PEARLPOINT CANCER SUPPORT REVENUE 174,788
SCHEDULE D, PAGE 4, PART XI, LINE 4BPEARLPOINT MANAGEMENT FEES 118,848 LOSS ON SALE OF ASSET -5,434,223
SCHEDULE D, PAGE 4, PART XII, LINE 2DLLS CANADA EXPENSES 5,085,686 PEARLPOINT CANCER SUPPORT EXPENSES 332,429 LOSS ON SALE OF ASSET 5,434,223
SCHEDULE D, PAGE 4, PART XII, LINE 4BLLS CANADA FOREIGN CURRENCY ADJ -184,000

Schedule F IRS990ScheduleF

FieldValueIRS element (for citing)
Grant Records MaintainedYes (true)GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (5 entries)

RegionRegionTxtEmployeeEmployeeCntType Of Activities ConductedTypeOfActivitiesConductedTxtSpecific Services ProvidedSpecificServicesProvidedTxtRegion Total ExpendituresRegionTotalExpendituresAmtOfficesOfficesCnt
CENTRAL AMERICA & CARIBBEAN1INVESTMENTSINVESTMENTS$3,543,591
EAST ASIA5RESEARCH FUNDINGRESEARCH GRANTS$824,166
NORTH AMERICA7RESEARCH FUNDINGRESEARCH GRANTS$7,043,0377
EUROPE7RESEARCH FUNDINGRESEARCH GRANTS$1,423,474
EUROPE1INVESTMENTSINVESTMENTS$980,649
FieldValueIRS element (for citing)
Subtotal Offices7SubtotalOfficesCnt
Subtotal Employees21SubtotalEmployeesCnt
Total Office7TotalOfficeCnt
Total Employee21TotalEmployeeCnt
Subtotal Spent$13,814,917SubtotalSpentAmt
Total Spent$13,814,917TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (24 entries)

RegionRegionTxtPurpose Of GrantPurposeOfGrantTxtCash GrantCashGrantAmtManner Of Cash DisbursementMannerOfCashDisbursementTxtValuation Method UsedValuationMethodUsedDesc
EAST ASIA & PACIFICRESEARCH GRANT$100,000WIREFMV
EAST ASIA & PACIFICRESEARCH GRANT$60,000WIREFMV
EAST ASIA & PACIFICRESEARCH GRANT$199,175WIREFMV
EAST ASIA & PACIFICRESEARCH GRANT$199,991CHECKFMV
EAST ASIA & PACIFICRESEARCH GRANT$200,000WIREFMV
EUROPERESEARCH GRANT$65,583WIREFMV
NORTH AMERICARESEARCH GRANT$60,000CHECKFMV
NORTH AMERICARESEARCH GRANT$200,000CHECKFMV
NORTH AMERICARESEARCH GRANT$200,000CHECKFMV
NORTH AMERICARESEARCH GRANT$1,000,000CHECKFMV
NORTH AMERICARESEARCH GRANT$1,000,000CHECKFMV
NORTH AMERICARESEARCH GRANT$300,000CHECKFMV
NORTH AMERICARESEARCH GRANT$65,000CHECKFMV
NORTH AMERICATHERAPY ACCELERATION$11,655CHECKFMV
NORTH AMERICATHERAPY ACCELERATION$11,655CHECKFMV
NORTH AMERICARESEARCH GRANT$4,194,727WIREFMV
EAST ASIA & PACIFICRESEARCH GRANT$65,000WIREFMV
EUROPETHERAPY ACCELERATION$250,000WIREFMV
EUROPERESEARCH GRANT$399,558WIREFMV
EUROPERESEARCH GRANT$200,000WIREFMV
EUROPERESEARCH GRANT$110,000WIREFMV
EUROPERESEARCH GRANT$133,333WIREFMV
EUROPERESEARCH GRANT$65,000WIREFMV
EUROPERESEARCH GRANT$200,000WIREFMV
FieldValueIRS element (for citing)
Total Other Org19TotalOtherOrgCnt
Transfer To Foreign CorpYes (true)TransferToForeignCorpInd
Interest In Foreign TrustfalseInterestInForeignTrustInd
Foreign Corp OwnershipYes (true)ForeignCorpOwnershipInd
Passive Foreign Investmest CoYes (true)PassiveForeignInvestmestCoInd
Foreign PartnershipfalseForeignPartnershipInd
Boycott CountriesfalseBoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE F, PAGE 1, PART I, LINE 2FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. THE ACCOUNTING METHOD UTILIZED FOR GRANTS REPORTED ON PART II IS THE ACCRUAL METHOD AS CONSISTENT WITH BOOKS AND RECORDS.
SCHEDULE F, PAGE 1, PART I, LINE 3CENTRAL AMERICA & CARIBBEAN 0 3,543,591 EAST ASIA 824,166 0 NORTH AMERICA 7,043,037 0 EUROPE 1,423,474 0 EUROPE 0 980,649

Schedule G IRS990ScheduleG

FieldValueIRS element (for citing)
Mail SolicitationsYes (X)MailSolicitationsInd
Email SolicitationsYes (X)EmailSolicitationsInd
Phone SolicitationsYes (X)PhoneSolicitationsInd
In Person SolicitationsYes (X)InPersonSolicitationsInd
Solicitation Of Non Govt GrantsYes (X)SolicitationOfNonGovtGrantsInd
Special Fundraising EventsYes (X)SpecialFundraisingEventsInd
Agrmt Prof Fundraising ActyYes (true)AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp (4 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdActivityActivityTxtFundraiser Control Of FundsFundraiserControlOfFundsIndRetained By ContractorRetainedByContractorAmtNet To OrganizationNetToOrganizationAmt
MAIL AMERICA COMMUNICATIONS INC
174 ELKTON FARM ROADFORESTVA24551DIRECT MAIfalse$1,129,235-$1,129,235
THOMPSON HABIB & DENISON
80 HAYDEN AVENUE SUITE 300LEXINGTONMA02421DIRECT MAIfalse$623,839-$623,839
THE HERITAGE COMPANY INC
PO BOX 16325LITTLE ROCKAR722316325DIRECT MAIfalse$280,024-$280,024
COINSTAR
1800 114TH AVENUE SEBELLEVUEWA98004COIN COLLEfalse$27,462-$27,462
FieldValueIRS element (for citing)
Total Retained By Contractors$2,060,560TotalRetainedByContractorsAmt
Total Net To Organization-$2,060,560TotalNetToOrganizationAmt
All StatesAll StatesAllStatesCd

Fundraising Event Information FundraisingEventInformationGrp

FieldValueIRS element (for citing)
Event1LAKE TAHOE BIKEEvent1Nm
Gross Receipts Event1$3,274,204GrossReceiptsEvent1Amt
Charitable Contri Event1$3,046,757CharitableContriEvent1Amt
Gross Revenue Event1$227,447GrossRevenueEvent1Amt
Non Cash Prizes Event1$80,220NonCashPrizesEvent1Amt
Rent Facility Costs Event1$523RentFacilityCostsEvent1Amt
Food And Beverage Event1$50,223FoodAndBeverageEvent1Amt
Entertainment Event1$2,310EntertainmentEvent1Amt
Other Direct Expenses Event1$248,392OtherDirectExpensesEvent1Amt
Event2DC LEUKEMIA BALEvent2Nm
Gross Receipts Event2$3,088,181GrossReceiptsEvent2Amt
Charitable Contri Event2$1,763,429CharitableContriEvent2Amt
Gross Revenue Event2$1,324,752GrossRevenueEvent2Amt
Non Cash Prizes Event2$5,309NonCashPrizesEvent2Amt
Rent Facility Costs Event2$729,071RentFacilityCostsEvent2Amt
Food And Beverage Event2$330,743FoodAndBeverageEvent2Amt
Entertainment Event2$285,830EntertainmentEvent2Amt
Other Direct Expenses Event2$32,088OtherDirectExpensesEvent2Amt
Other Events Total487OtherEventsTotalCnt
Gross Receipts Other Events$178,221,039GrossReceiptsOtherEventsAmt
Charitable Contri Other Events$159,800,502CharitableContriOtherEventsAmt
Gross Revenue Other Events$18,420,537GrossRevenueOtherEventsAmt
Non Cash Prizes Other Events$4,755,183NonCashPrizesOtherEventsAmt
Rent Fclty Costs Other Events$8,712,085RentFcltyCostsOtherEventsAmt
Food And Beverage Other Events$3,604,904FoodAndBeverageOtherEventsAmt
Entertainment Other Events$868,603EntertainmentOtherEventsAmt
Oth Direct Expnss Other Events$5,196,059OthDirectExpnssOtherEventsAmt
Gross Receipts Total$184,583,424GrossReceiptsTotalAmt
Charitable Contributions Tot$164,610,688CharitableContributionsTotAmt
Gross Revenue Total Events$19,972,736GrossRevenueTotalEventsAmt
Non Cash Prizes Total Events$4,840,712NonCashPrizesTotalEventsAmt
Rent Fclty Costs Total Events$9,441,679RentFcltyCostsTotalEventsAmt
Food And Beverage Total Events$3,985,870FoodAndBeverageTotalEventsAmt
Entertainment Total Events$1,156,743EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events$5,476,539OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events$24,901,543DirectExpenseSummaryEventsAmt
Net Income Summary-$4,928,807NetIncomeSummaryAmt

Gaming Information GamingInformationGrp

FieldValueIRS element (for citing)
Volunteer Labor BingofalseVolunteerLaborBingoInd
Volunteer Labor Pull TabsfalseVolunteerLaborPullTabsInd
Gross Revenue Other Gaming$925,424GrossRevenueOtherGamingAmt
Cash Prizes Other Gaming$2,000CashPrizesOtherGamingAmt
Non Cash Prizes Other Gaming$244,953NonCashPrizesOtherGamingAmt
Volunteer Labor Other GamingYes (true)VolunteerLaborOtherGamingInd
Volunteer Labor Other Gaming0.90000VolunteerLaborOtherGamingPct
Gross Revenue Total Gaming$925,424GrossRevenueTotalGamingAmt
Cash Prizes Total Gaming$2,000CashPrizesTotalGamingAmt
Non Cash Prizes Total Gaming$244,953NonCashPrizesTotalGamingAmt
Direct Expense Summary Gaming$246,953DirectExpenseSummaryGamingAmt
Net Gaming Income Summary$678,471NetGamingIncomeSummaryAmt
FieldValueIRS element (for citing)
States Where Gaming ConductedALStatesWhereGamingConductedCd
States Where Gaming ConductedDEStatesWhereGamingConductedCd
States Where Gaming ConductedDCStatesWhereGamingConductedCd
States Where Gaming ConductedNYStatesWhereGamingConductedCd
States Where Gaming ConductedOHStatesWhereGamingConductedCd
States Where Gaming ConductedORStatesWhereGamingConductedCd
States Where Gaming ConductedPAStatesWhereGamingConductedCd
States Where Gaming ConductedTXStatesWhereGamingConductedCd
States Where Gaming ConductedIAStatesWhereGamingConductedCd
LicensedYes (true)LicensedInd
License Suspended EtcfalseLicenseSuspendedEtcInd
Gaming With NonmembersfalseGamingWithNonmembersInd
Member Of Other EntityfalseMemberOfOtherEntityInd
Gaming Own Facility0.25000GamingOwnFacilityPct
Gaming Other Facility0.75000GamingOtherFacilityPct
Individual With BooksROSEMARIE LOFFREDOIndividualWithBooksNm

Persons With Books US Address PersonsWithBooksUSAddress

FieldValueIRS element (for citing)
Address Line13 INTERNATIONAL DRIVE SUITE 200AddressLine1Txt
CityRYE BROOKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10573ZIPCd
FieldValueIRS element (for citing)
Cntrct With3rd Prty For Game RevfalseCntrctWith3rdPrtyForGameRevInd
Gaming Manager PersonSEE SCHEDULE G PART IVGamingManagerPersonNm
Charitable Distribution RqrfalseCharitableDistributionRqrInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE G, PAGE 2, PART III, LINE 9TEXAS, IOWA
SCHEDULE G, PART IVSCHEDULE G PART I, LINE 2B LLS USED MAIL AMERICA COMMUNICATIONS, THOMPSON, HABIB & DENSION, AND THE HERITAGE COMPANY FOR ITS NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS. THESE PROGRAMS GENERATED GROSS RECEIPTS OF 20,728,022 DURING FISCAL YEAR 2017. LLS USED COINSTAR FOR ITS COIN COLLECTION DURING THE FISCAL YEAR 2017. SCHEDULE G PART II - LINE 2 CONTRIBUTIONS REPRESENT THE CASH DONATIONS IN EXCESS OF THE FAIR MARKET VALUE OF BENEFITS PROVIDED TO THE DONOR. SCHEDULE G PART III - LINE 16 THE LEUKEMIA AND LYMPHOMA SOCIETY DOES NOT HAVE AN OVERALL MANAGER FOR GAMING ACTIVITIES. EACH GAMING EVENT IS MANAGED LOCALLY BY THE SPECIFIC CHAPTER STAFF.

Schedule I IRS990ScheduleI

FieldValueIRS element (for citing)
Grant Records MaintainedYes (true)GrantRecordsMaintainedInd

Recipient Table RecipientTable (216 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdRecipient EINRecipientEINIRC SectionIRCSectionDescCash GrantCashGrantAmtValuation Method UsedValuationMethodUsedDescPurpose Of GrantPurposeOfGrantTxt
UNIVERSITY OF ALABAMA AT BIRMINGHAM
1530 3RD AVENUE SOUTH SUITE 1170BIRMINGHAMAL3529401116360053963$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF ALABAMA AT BIRMINGHAM
1530 3RD AVENUE SOUTH SUITE 1170BIRMINGHAMAL3529401116360053963$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF ARIZONA
1303 E UNIVERSITY BLVD BOX 3TUCSONAZ857217426526893$200,000ACCRUALRESEARCH GRANT
DECOY BIOSCIENCES AGREEMENT (PURCHA
3830 VALLEY CENTRE DR SUITE 705 PSAN DIEGOCA92130463416861$50,003FMVTHERAPY ACCELERATION
FORTY SEVEN INC
1490 OBRIEN DRIVE SUITE AMENLO PARKCA94025474065674$1,000,000FMVTHERAPY ACCELERATION
IMMUNGENE INC
480 CONSTITUTION AVENUECAMARILLOCA93012261339641$500,000FMVTHERAPY ACCELERATION
KITE PHARMA INC
2225 COLORADO AVENUESANTA MONICACA90404271524986$200,000FMVTHERAPY ACCELERATION
KITE PHARMA INC
2225 COLORADO AVENUESANTA MONICACA90404271524986$400,000FMVTHERAPY ACCELERATION
KITE PHARMA INC
2225 COLORADO AVENUESANTA MONICACA90404271524986$400,000FMVTHERAPY ACCELERATION
BECKMAN RESEARCH INSTITUTE OF CITY
1500 DUARTE ROADDUARTECA9101030009534322103$110,000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF CITY
1500 DUARTE ROADDUARTECA9101030009534322103$110,000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF CITY
1500 DUARTE ROADDUARTECA9101030009534322103$200,000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF CITY
1500 DUARTE ROADDUARTECA9101030009534322103$300,000ACCRUALRESEARCH GRANT
CEDARS-SINAI MEDICAL CENTER
8700 BEVERLY BOULEVARD 65-WIL 115LOS ANGELESCA900489516446003$133,333ACCRUALRESEARCH GRANT
CHILDREN'S HOSPITAL LOS ANGELES
4650 SUNSET BLVD MAIL STOP 54LOS ANGELESCA900279516909773$200,000ACCRUALRESEARCH GRANT
LA JOLLA INSTITUTE FOR ALLERGY AND
9420 ATHENA CIRCLELA JOLLACA920373303286883$60,000ACCRUALRESEARCH GRANT
LELAND STANFORD JUNIOR UNIVERSITY
STANFORD UNIVERSITY LOCKBOX PO BOXSAN FRANCISCOCA9414442539411563653$110,000ACCRUALRESEARCH GRANT
LELAND STANFORD JUNIOR UNIVERSITY
STANFORD UNIVERSITY LOCKBOX PO BOXSAN FRANCISCOCA9414442539411563653$65,000ACCRUALRESEARCH GRANT
LELAND STANFORD JUNIOR UNIVERSITY
STANFORD UNIVERSITY LOCKBOX PO BOXSAN FRANCISCOCA9414442539411563653$55,000ACCRUALRESEARCH GRANT
LELAND STANFORD JUNIOR UNIVERSITY
STANFORD UNIVERSITY LOCKBOX PO BOXSAN FRANCISCOCA9414442539411563653$55,000ACCRUALRESEARCH GRANT
LELAND STANFORD JUNIOR UNIVERSITY
STANFORD UNIVERSITY LOCKBOX PO BOXSAN FRANCISCOCA9414442539411563653$60,000ACCRUALRESEARCH GRANT
LELAND STANFORD JUNIOR UNIVERSITY
STANFORD UNIVERSITY LOCKBOX PO BOXSAN FRANCISCOCA9414442539411563653$200,000ACCRUALRESEARCH GRANT
LELAND STANFORD JUNIOR UNIVERSITY
STANFORD UNIVERSITY LOCKBOX PO BOXSAN FRANCISCOCA9414442539411563653$200,000ACCRUALRESEARCH GRANT
LELAND STANFORD JUNIOR UNIVERSITY
STANFORD UNIVERSITY LOCKBOX PO BOXSAN FRANCISCOCA9414442539411563653$100,000ACCRUALRESEARCH GRANT
SANFORD BURNHAM PREBYS MEDICAL DISC
10901 NORTH TORREY PINES ROADLA JOLLACA920375101971083$60,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
11000 KINROSS AVE SUITE 102LOS ANGELESCA900959560061433$55,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRIVE MC 0009LA JOLLACA9209300099560061443$1,250,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1855 FOLSOM STREET SUITE 425SAN FRANCISCOCA941439460364933$60,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1855 FOLSOM STREET SUITE 425SAN FRANCISCOCA941439460364933$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
1855 FOLSOM STREET SUITE 425SAN FRANCISCOCA941439460364933$300,000ACCRUALRESEARCH GRANT
THE SCRIPPS RESEARCH INSTITUTE
10550 NORTH TORREY PINES ROAD TPC-7LA JOLLACA920373304359543$55,000ACCRUALRESEARCH GRANT
UNIVERSITY OF CALIFORNIA SAN FRANC
1855 FOLSOM STREET SUITE 425SAN FRANCISCOCA941439460364933$55,000ACCRUALRESEARCH GRANT
UNIVERSITY OF CALIFORNIA SAN FRANC
1855 FOLSOM STREET SUITE 425SAN FRANCISCOCA941439460364933$55,000ACCRUALRESEARCH GRANT
REGENTS OF THE UNIVERSITY OF COLORA
579 UCB3100 MARINE STREETBOULDERCO8030905728460005553$54,000FMVTHERAPY ACCELERATION
YALE UNIVERSITY
PO BOX 208327NEW HAVENCT0652083270606469733$60,000ACCRUALRESEARCH GRANT
YALE UNIVERSITY
PO BOX 208327NEW HAVENCT0652083270606469733$200,000ACCRUALRESEARCH GRANT
YALE UNIVERSITY
PO BOX 208327NEW HAVENCT0652083270606469733$200,000ACCRUALRESEARCH GRANT
IWMF
6144 CLARK CENTER AVESARASOTAFL342385417844263$125,000ACCRUALRESEARCH GRANT
EMORY UNIVERSITY
1599 CLIFTON RD NE 4TH FL 1599-0ATLANTAGA3032242505821379933$67,000ACCRUALRESEARCH GRANT
EMORY UNIVERSITY
1599 CLIFTON RD NE 4TH FL 1599-0ATLANTAGA3032242505821379933$200,000ACCRUALRESEARCH GRANT
H LEE MOFFITT CANCER CENTER & RESE
PO BOX 742801ATLANTAGA3037428015932386343$449,155ACCRUALRESEARCH GRANT
THE UNIVERSITY OF NORTH CAROLINA AT
PO BOX 402420ATLANTAGA3038424205660013933$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MIAMI
PO BOX 405803ATLANTAGA3038458035906244583$100,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MIAMI
PO BOX 405803ATLANTAGA3038458035906244583$150,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MIAMI
PO BOX 405803ATLANTAGA3038458035906244583$300,000ACCRUALRESEARCH GRANT
JOHNS HOPKINS UNIVERSITY CEN
12529 COLLECTIONS CENTER DRIVECHICAGOIL606935205951103$250,000FMVTHERAPY ACCELERATION
JOHNS HOPKINS UNIVERSITY CEN
12529 COLLECTIONS CENTER DRIVECHICAGOIL606935205951103$250,000FMVTHERAPY ACCELERATION
MPNRF
180 N MICHIGAN AVENUE SUITE 1870CHICAGOIL606013643309673$200,000ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY
633 CLARK - ROOM G547EVANSTONIL602083621678173$110,000ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY
633 CLARK - ROOM G547EVANSTONIL602083621678173$133,333ACCRUALRESEARCH GRANT
THE JOHNS HOPKINS UNIVERSITY SCHOOL
12529 COLLECTIONS CENTER DRIVECHICAGOIL606935205951103$55,000ACCRUALRESEARCH GRANT
THE JOHNS HOPKINS UNIVERSITY SCHOOL
12529 COLLECTIONS CENTER DRIVECHICAGOIL606935205951103$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF CHICAGO
5841 S MARYLAND AVE MC6092CHICAGOIL606373621771393$67,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF CHICAGO
5841 S MARYLAND AVE MC6092CHICAGOIL606373621771393$60,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF CHICAGO
5841 S MARYLAND AVE MC6092CHICAGOIL606373621771393$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF CHICAGO
5841 S MARYLAND AVE MC6092CHICAGOIL606373621771393$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF CHICAGO
5841 S MARYLAND AVE MC6092CHICAGOIL606373621771393$200,000ACCRUALRESEARCH GRANT
INDIANA UNIVERSITY
509 E 3RD STREETBLOOMINGTONIN4740136543560189403$110,000ACCRUALRESEARCH GRANT
INDIANA UNIVERSITY-PURDUE UNIVERSIT
980 INDIANA AVENUE LOCKEFIELD 2232INDIANAPOLISIN4620229153560016733$133,333ACCRUALRESEARCH GRANT
UNIVERSITY OF IOWA
GILMORE HALL UNIVERSITY OF IOWAIOWA CITYIA522424260048133$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF IOWA
GILMORE HALL UNIVERSITY OF IOWAIOWA CITYIA522424260048133$200,000ACCRUALRESEARCH GRANT
CONSTELLATION PHARMACEUTICAL
215 FIRST STREET SUITE 200CAMBRIDGEMA02142261741721$250,000FMVTHERAPY ACCELERATION
CONSTELLATION PHARMACEUTICAL
215 FIRST STREET SUITE 200CAMBRIDGEMA02142261741721$350,000FMVTHERAPY ACCELERATION
DANA FARBER CANCER INSTITU
450 BROOKLINE AVENUE ROOM M557BOSTONMA0221554500422630403$83,325FMVTHERAPY ACCELERATION
DANA FARBER CANCER INSTITU
450 BROOKLINE AVENUE ROOM M557BOSTONMA0221554500422630403$83,325FMVTHERAPY ACCELERATION
KDAC THERAPEUTICS
400 TECHNOLOGY SQUARE 10TH FLOORCAMBRIDGEMA02139463394196$300,000FMVTHERAPY ACCELERATION
UNIVERSITY OF MARYLAND AT BALTIMORE
PO BOX 41428BALTIMOREMD2120364285260020333$200,000ACCRUALRESEARCH GRANT
BETH ISRAEL DEACONESS MEDICAL CENTE
330 BROOKLINE AVE BR-0259BOSTONMA022150421038813$110,000ACCRUALRESEARCH GRANT
BETH ISRAEL DEACONESS MEDICAL CENTE
330 BROOKLINE AVE BR-0259BOSTONMA022150421038813$110,000ACCRUALRESEARCH GRANT
BETH ISRAEL DEACONESS MEDICAL CENTE
330 BROOKLINE AVE BR-0259BOSTONMA022150421038813$55,000ACCRUALRESEARCH GRANT
BOSTON CHILDREN'S HOSPITAL
PO BOX 414413BOSTONMA0224144130427744413$110,000ACCRUALRESEARCH GRANT
BOSTON CHILDREN'S HOSPITAL
PO BOX 414413BOSTONMA0224144130427744413$67,000ACCRUALRESEARCH GRANT
BOSTON CHILDREN'S HOSPITAL
PO BOX 414413BOSTONMA0224144130427744413$55,000ACCRUALRESEARCH GRANT
BOSTON CHILDREN'S HOSPITAL
PO BOX 414413BOSTONMA0224144130427744413$55,000ACCRUALRESEARCH GRANT
BOSTON CHILDREN'S HOSPITAL
PO BOX 414413BOSTONMA0224144130427744413$200,000ACCRUALRESEARCH GRANT
BOSTON CHILDREN'S HOSPITAL
PO BOX 414413BOSTONMA0224144130427744413$133,333ACCRUALRESEARCH GRANT
BRIGHAM AND WOMENS HOSPITAL
PO BOX 3149BOSTONMA0224131490423129093$110,000ACCRUALRESEARCH GRANT
BRIGHAM AND WOMENS HOSPITAL
PO BOX 3149BOSTONMA0224131490423129093$67,000ACCRUALRESEARCH GRANT
BRIGHAM AND WOMENS HOSPITAL
PO BOX 3149BOSTONMA0224131490423129093$55,000ACCRUALRESEARCH GRANT
BRIGHAM AND WOMENS HOSPITAL
PO BOX 3149BOSTONMA0224131490423129093$200,000ACCRUALRESEARCH GRANT
BRIGHAM AND WOMENS HOSPITAL
PO BOX 3149BOSTONMA0224131490423129093$200,000ACCRUALRESEARCH GRANT
BRIGHAM AND WOMENS HOSPITAL
PO BOX 3149BOSTONMA0224131490423129093$200,000ACCRUALRESEARCH GRANT
BROAD INSTITUTE INC
7 CAMBRIDGE CENTERCAMBRIDGEMA021422634287813$60,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$55,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$15,477ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$67,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$55,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$55,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$46,647ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$55,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$199,999ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$1,250,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$1,000,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$300,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE MAIL STOP BP45BOSTONMA022150422630403$133,333ACCRUALRESEARCH GRANT
HARVARD MEDICAL SCHOOL
PO BOX 415649BOSTONMA0224156490421035803$60,000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
MGH RESEARCH FINANCE PO BOX 414876BOSTONMA0224148760415646553$110,000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
MGH RESEARCH FINANCE PO BOX 414876BOSTONMA0224148760415646553$55,000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
MGH RESEARCH FINANCE PO BOX 414876BOSTONMA0224148760415646553$200,000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
MGH RESEARCH FINANCE PO BOX 414876BOSTONMA0224148760415646553$200,000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
MGH RESEARCH FINANCE PO BOX 414876BOSTONMA0224148760415646553$200,000ACCRUALRESEARCH GRANT
MASSACHUSETTS INSTITUTE OF TECHNOLO
77 MASSACHUSETTS AVE NE18-901CAMBRIDGEMA021390421035943$200,000ACCRUALRESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
PO BOX 415026BOSTONMA0224141501355623083$110,000ACCRUALRESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
PO BOX 415026BOSTONMA0224141501355623083$60,000ACCRUALRESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
PO BOX 415026BOSTONMA0224141501355623083$300,000ACCRUALRESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
PO BOX 415026BOSTONMA0224141501355623083$200,000ACCRUALRESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
PO BOX 415026BOSTONMA0224141501355623083$1,250,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MASSACHUSETTS MEDICAL
55 LAKE AVENUE NORTHWORCESTERMA0165500020431673523$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MASSACHUSETTS MEDICAL
55 LAKE AVENUE NORTHWORCESTERMA0165500020431673523$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MASSACHUSETTS MEDICAL
55 LAKE AVENUE NORTHWORCESTERMA0165500020431673523$65,000ACCRUALRESEARCH GRANT
MAYO CLINIC ARIZONA
MAYO CLINIC RESEARCH PO BOX 860334MINNEAPOLISMN5548603348608001503$110,000ACCRUALRESEARCH GRANT
MAYO CLINIC ROCHESTER
MAYO CLINIC RESEARCH PO BOX 860334MINNEAPOLISMN5548603344160117023$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MINNESOTA TWIN CITIE
450 MCNAMARA ALUMNI CENTERMINNEAPOLISMN554144160075133$200,000ACCRUALRESEARCH GRANT
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRST LOUISMO631304306536113$110,000ACCRUALRESEARCH GRANT
WASHINGTON UNIVERSITY SCHOOL OF MED
700 ROSEDALE AVENUE CAMPUS BOX 1034ST LOUISMO6311214084306536113$110,000ACCRUALRESEARCH GRANT
WASHINGTON UNIVERSITY SCHOOL OF MED
700 ROSEDALE AVENUE CAMPUS BOX 1034ST LOUISMO6311214084306536113$110,000ACCRUALRESEARCH GRANT
WASHINGTON UNIVERSITY SCHOOL OF MED
700 ROSEDALE AVENUE CAMPUS BOX 1034ST LOUISMO6311214084306536113$200,000ACCRUALRESEARCH GRANT
WASHINGTON UNIVERSITY SCHOOL OF MED
700 ROSEDALE AVENUE CAMPUS BOX 1034ST LOUISMO6311214084306536113$200,000ACCRUALRESEARCH GRANT
ALBERT EINSTEIN COLLEGE OF MEDICINE
RESEARCH FINANCE 1300 MORRIS PARK ABRONXNY104614722090563$110,000ACCRUALRESEARCH GRANT
ALBERT EINSTEIN COLLEGE OF MEDICINE
RESEARCH FINANCE 1300 MORRIS PARK ABRONXNY104614722090563$200,000ACCRUALRESEARCH GRANT
ALBERT EINSTEIN COLLEGE OF MEDICINE
RESEARCH FINANCE 1300 MORRIS PARK ABRONXNY104614722090563$200,000ACCRUALRESEARCH GRANT
COLD SPRING HARBOR LABORATORY
1 BUNGTOWN ROAD PO BOX 100COLD SPRING HARBORNY117241120133033$110,000ACCRUALRESEARCH GRANT
ICAHN SCHOOL OF MEDICINE AT MOUNT S
ONE GUSTAVE L LEVY PLACE BOX 350NEW YORKNY100291361711973$110,000ACCRUALRESEARCH GRANT
ICAHN SCHOOL OF MEDICINE AT MOUNT S
ONE GUSTAVE L LEVY PLACE BOX 350NEW YORKNY100291361711973$300,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
PO BOX 026338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
PO BOX 026338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
PO BOX 026338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
PO BOX 026338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
PO BOX 026338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
PO BOX 026338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
PO BOX 026338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
PO BOX 026338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
PO BOX 026338NEW YORKNY100871319242363$65,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
PO BOX 026338NEW YORKNY100871319242363$65,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
PO BOX 026338NEW YORKNY100871319242363$67,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
PO BOX 026338NEW YORKNY100871319242363$67,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
PO BOX 026338NEW YORKNY100871319242363$55,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
PO BOX 026338NEW YORKNY100871319242363$59,999ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
PO BOX 026338NEW YORKNY100871319242363$200,000ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
PO BOX 026338NEW YORKNY100871319242363$133,333ACCRUALRESEARCH GRANT
MEMORIAL SLOAN KETTERING CANCER CEN
PO BOX 026338NEW YORKNY100871319242363$2,000,000ACCRUALRESEARCH GRANT
NEW YORK UNIVERSITY MEDICAL CENTER
665 BROADWAY SUITE 801NEW YORKNY1001223311355623083$55,000ACCRUALRESEARCH GRANT
RESEARCH FOUNDATION OF SUNY AT UPST
750 E ADAMS STREET ROOM 209 CABSYRACUSENY132101413683613$110,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
615 WEST 131ST STREET - MAIL CODE 8NEW YORKNY100271355980933$110,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
615 WEST 131ST STREET - MAIL CODE 8NEW YORKNY100271355980933$110,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
615 WEST 131ST STREET - MAIL CODE 8NEW YORKNY100271355980933$65,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
615 WEST 131ST STREET - MAIL CODE 8NEW YORKNY100271355980933$67,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
615 WEST 131ST STREET - MAIL CODE 8NEW YORKNY100271355980933$60,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
615 WEST 131ST STREET - MAIL CODE 8NEW YORKNY100271355980933$200,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
615 WEST 131ST STREET - MAIL CODE 8NEW YORKNY100271355980933$200,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
615 WEST 131ST STREET - MAIL CODE 8NEW YORKNY100271355980933$500,000ACCRUALRESEARCH GRANT
WEILL CORNELL MEDICAL COLLEGE
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$110,000ACCRUALRESEARCH GRANT
WEILL CORNELL MEDICAL COLLEGE
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$110,000ACCRUALRESEARCH GRANT
WEILL CORNELL MEDICAL COLLEGE
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$60,000ACCRUALRESEARCH GRANT
WEILL CORNELL MEDICAL COLLEGE
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$200,000ACCRUALRESEARCH GRANT
WEILL CORNELL MEDICAL COLLEGE
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$200,000ACCRUALRESEARCH GRANT
WEILL CORNELL MEDICAL COLLEGE
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$400,000ACCRUALRESEARCH GRANT
WEILL CORNELL MEDICAL COLLEGE
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$149,985ACCRUALRESEARCH GRANT
CHARLOTTE MECKLENBURG HOSPITAL AUTH
208 EAST BOULEVARDCHARLOTTENC282035605299453$110,000ACCRUALRESEARCH GRANT
DUKE UNIVERSITY MEDICAL CENTER
324 BLACKWLL STREET WASHINGTON BLDDURHAMNC277085605321293$200,000ACCRUALRESEARCH GRANT
DUKE UNIVERSITY MEDICAL CENTER
324 BLACKWLL STREET WASHINGTON BLDDURHAMNC277085605321293$200,000ACCRUALRESEARCH GRANT
CASE WESTERN RESERVE UNIVERSITY SCH
10900 EUCLID AVENUE BIOENTERPRISE BCLEVELANDOH4410670373410189923$200,000ACCRUALRESEARCH GRANT
CINCINNATI CHILDREN'S HOSPITAL MEDI
3333 BURNET AVENUECINCINATTIOH452293108339363$110,000ACCRUALRESEARCH GRANT
CINCINNATI CHILDREN'S RESEARCH FOUN
3333 BURNET AVENUECINCINNATIOH452293108339363$200,000ACCRUALRESEARCH GRANT
THE OHIO STATE UNIVERSITY
1960 KENNY ROAD THE OFFICE OF SPONSCOLUMBUSOH432103160259863$110,000ACCRUALRESEARCH GRANT
THE OHIO STATE UNIVERSITY
1960 KENNY ROAD THE OFFICE OF SPONSCOLUMBUSOH432103160259863$110,000ACCRUALRESEARCH GRANT
THE OHIO STATE UNIVERSITY
1960 KENNY ROAD THE OFFICE OF SPONSCOLUMBUSOH432103160259863$200,000ACCRUALRESEARCH GRANT
THE OHIO STATE UNIVERSITY
1960 KENNY ROAD THE OFFICE OF SPONSCOLUMBUSOH432103160259863$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF CINCINNATI
SRS-ACCOUNTING 51 GOODMAN DRIVE SCINCINNATIOH4522102223108965553$110,000ACCRUALRESEARCH GRANT
OREGON HEALTH & SCIENCE UNIVERSITY
3181 SW SAM JACKSON PARK ROAD MAILPORTLANDOR9723930982370831143$200,000ACCRUALRESEARCH GRANT
AMERICAN ASSOCIATION FOR CANC
615 CHESTNUT STREET 17TH FLOORPHILADELPHIAPA1910644042362516483$6,000FMVTHERAPY ACCELERATION
PERELMAN SCHOOL OF MEDICINE AT THE
3451 WALNUT STREET FRANKLIN BLDG P-PHILADELPHIAPA1910462052313526853$110,000ACCRUALRESEARCH GRANT
REGENTS OF THE UNIVERSITY OF MICHIG
BOX 223131PITTSBURGHPA1525121313860063093$110,000ACCRUALRESEARCH GRANT
REGENTS OF THE UNIVERSITY OF MICHIG
BOX 223131PITTSBURGHPA1525121313860063093$110,000ACCRUALRESEARCH GRANT
REGENTS OF THE UNIVERSITY OF MICHIG
BOX 223131PITTSBURGHPA1525121313860063093$110,000ACCRUALRESEARCH GRANT
REGENTS OF THE UNIVERSITY OF MICHIG
BOX 223131PITTSBURGHPA1525121313860063093$200,000ACCRUALRESEARCH GRANT
THE CHILDREN'S HOSPITAL OF PHILADEL
PO BOX 8500 LOCKBOX 1457PHILADELPHIAPA1917814572313521663$110,000ACCRUALRESEARCH GRANT
THE CHILDREN'S HOSPITAL OF PHILADEL
PO BOX 8500 LOCKBOX 1457PHILADELPHIAPA1917814572313521663$200,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF THE UNIVERSITY OF P
3451 WALNUT STREET FRANKLIN BLDG P-PHILADELPHIAPA1910462052313526853$55,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF THE UNIVERSITY OF P
3451 WALNUT STREET FRANKLIN BLDG P-PHILADELPHIAPA1910462052313526853$200,000ACCRUALRESEARCH GRANT
THE WISTAR INSTITUTE
3601 SPRUCE STREETPHILADELPHIAPA191042364343903$60,000ACCRUALRESEARCH GRANT
ST JUDE CHILDREN'S RESEARCH HOSPIT
PO BOX 1000 DEPT 949MEMPHISTN3814809496206460123$200,000ACCRUALRESEARCH GRANT
BAYLOR COLLEGE OF MEDICINE
ONE BAYLOR PLAZA MAIL STOP BCM-31HOUSTONTX770307416138783$200,000ACCRUALRESEARCH GRANT
BAYLOR COLLEGE OF MEDICINE
ONE BAYLOR PLAZA MAIL STOP BCM-31HOUSTONTX770307416138783$200,000ACCRUALRESEARCH GRANT
BAYLOR COLLEGE OF MEDICINE
ONE BAYLOR PLAZA MAIL STOP BCM-31HOUSTONTX770307416138783$200,000ACCRUALRESEARCH GRANT
BAYLOR COLLEGE OF MEDICINE
ONE BAYLOR PLAZA MAIL STOP BCM-31HOUSTONTX770307416138783$1,250,000ACCRUALRESEARCH GRANT
BAYLOR COLLEGE OF MEDICINE
ONE BAYLOR PLAZA MAIL STOP BCM-31HOUSTONTX770307416138783$100,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
PO BOX 4266HOUSTONTX7721042667460011183$110,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
PO BOX 4266HOUSTONTX7721042667460011183$110,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
PO BOX 4266HOUSTONTX7721042667460011183$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
PO BOX 4266HOUSTONTX7721042667460011183$200,000ACCRUALRESEARCH GRANT
UNIV OF TEXAS HEALTH SCIENCE CENTER
MAIL CODE 78287703 FLOYD CURL DRIVESAN ANTONIOTX7822939007415860313$200,000ACCRUALRESEARCH GRANT
UT SOUTHWESTERN MEDICAL CENTER
PO BOX 841753DALLASTX7528417537560028683$110,000ACCRUALRESEARCH GRANT
VANDERBILT UNIVERSITY MEDICAL CENTE
PO BOX 121236DALLASTX753126204768223$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF TEXAS
PO BOX 4390HOUSTONTX7721043903007101453$250,000FMVTHERAPY ACCELERATION
THE UNIVERSITY OF UTAH
201 S PRESIDENTS CIRCLE RM 145SALT LAKE CITYUT8411290038760005253$110,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF UTAH
201 S PRESIDENTS CIRCLE RM 145SALT LAKE CITYUT8411290038760005253$67,000ACCRUALRESEARCH GRANT
VIRGINIA COMMONWEALTH UNIVERSITY
PO BOX 843039RICHMONDVA2328430395460017583$300,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-300SEATTLEWA9810910242371560713$110,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-300SEATTLEWA9810910242371560713$110,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-300SEATTLEWA9810910242371560713$67,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-300SEATTLEWA9810910242371560713$200,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-300SEATTLEWA9810910242371560713$200,000ACCRUALRESEARCH GRANT
CHILDREN'S NATIONAL HEALTH SYSTEM
111 MICHIGAN AVENUE NW CRI CENTERWASHINGTON DCDC200105216544533$200,000ACCRUALRESEARCH GRANT
THE BOARD OF REGENTS OF THE UNIVERS
21 N PARK ST SUITE 6401MADISONWI5371512183960064923$110,000ACCRUALRESEARCH GRANT
THE BOARD OF REGENTS OF THE UNIVERS
21 N PARK ST SUITE 6401MADISONWI5371512183960064923$200,000ACCRUALRESEARCH GRANT
FieldValueIRS element (for citing)
Total501c3 Org207Total501c3OrgCnt
Total Other Org9TotalOtherOrgCnt

Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp (8 entries)

Grant TypeGrantTypeTxtRecipientRecipientCntCash GrantCashGrantAmt
COPAY ASSISTANCE CLL5970$14,572,918
COPAY ASSISTANCE LYMPHOMA9488$12,493,774
COPAY ASSISTANCE MDS1568$3,419,824
COPAY ASSISTANCE MYELOMA11094$34,277,850
COPAY ASSISTANCE MANTEL1411$4,225,653
COPAY ASSISTANCE WALDENST1104$3,402,974
COPAY ASSISTANCE CML391$576,110
PATIENT TRAVEL ASSISTNCE3405$1,702,538

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE I, PAGE 1, PART I, LINE 2FormAndLineReferenceDesc
ExplanationFIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATIENTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTENTIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA.ExplanationTxt

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Compensation CommitteeYes (X)CompensationCommitteeInd
Independent ConsultantYes (X)IndependentConsultantInd
Form990 Of Other OrganizationsYes (X)Form990OfOtherOrganizationsInd
Compensation SurveyYes (X)CompensationSurveyInd
Board Or Committee ApprovalYes (X)BoardOrCommitteeApprovalInd
Severance PaymentYes (true)SeverancePaymentInd
Supplemental Nonqual Rtr PlanYes (true)SupplementalNonqualRtrPlanInd
Equity Based Comp ArrngmfalseEquityBasedCompArrngmInd
Comp Based On Revenue Of Flng OrgfalseCompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related OrgsfalseCompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng OrgfalseCompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd OrgsfalseCompBsdNetEarnsRltdOrgsInd
Any Non Fixed PaymentsYes (true)AnyNonFixedPaymentsInd
Initial Contract ExceptionfalseInitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (12 entries)

TitleTitleTxtBase Compensation Filing OrgBaseCompensationFilingOrgAmtOther Compensation Filing OrgOtherCompensationFilingOrgAmtDeferred Compensation Flng OrgDeferredCompensationFlngOrgAmtNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmtTotal Compensation Filing OrgTotalCompensationFilingOrgAmtBonus Filing OrganizationBonusFilingOrganizationAmount
LOUIS J DEGENNARO
PRESIDENT & CEO$491,307$30,954$79,209$22,089$623,559
ROSEMARIE A LOFFREDO
EVP - CFO$319,678$23,013$9,275$12,944$415,910$51,000
GORDON MILLER JR
SVP FINANCE$234,874$778$13,007$27,967$295,708$19,082
MARK ROITHMAYR - TERM 12312016
EVP CHIEF REL OFFICE$353,887$21,535$9,275$29,800$451,090$36,593
ANDREW S COCCARI
EVP CHIEF PROD OFFIC$319,590$1,664$744$29,376$383,874$32,500
ALICE O'ROURKE
EVP CHIEF DEV OFFICE$287,904$4,193$28,864$320,961
LEE M GREENBERGER
SVP CHIEF SCIEN OFFI$284,352$6,765$9,275$29,417$344,374$14,565
PAULETTE DAMIANO - TERM 6302016
VP ORG DEV & CHANGE$98,397$221,169$4,688$15,293$339,547
COKER POWELL
SVP, LTN CAMPAIGN$203,284$18,000$4,627$22,450$266,361$18,000
DEBORAH MATZ
SVP, LEGAL AND ERM$217,336$3,137$6,253$23,303$261,097$11,068
MICHELE PRZYPYSZNY - TERM 7212016
EXECUTIVE DIRECTOR$120,007$125,726$6,076$6,876$258,685
GEORGE J OMIROS-TERM APR15
EVP-CHIEF CAMP&FIELD$111,126$111,126

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE J, PAGE 1, PART I, LINE 4LOUIS J. DEGENNARO 0 65,000 0 PAULETTE DAMIANO - TERM 6/30/2016 220,328 0 0 MICHELE PRZYPYSZNY - TERM 7/21/2016 125,350 0 0 GEORGE J. OMIROS-TERM APR15 111,126 0 0
SCHEDULE J, PAGE 1, PART I, LINE 7BONUSES WERE PAID BASED ON THE ACHIEVEMENT OF THE EMPLOYEE INDIVIDUAL PERFORMANCE. BONUSES WERE CAPPED ACCORDING TO LLS'S POLICY. THESE AMOUNTS ARE REPORTED ON SCHEDULE J PART II, COLUMN (B)(II).

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTradedGrp

FieldValueIRS element (for citing)
Non Cash CheckboxYes (X)NonCashCheckboxInd
Contribution181ContributionCnt
Noncash Contributions Rpt F990$3,455,301NoncashContributionsRptF990Amt
Method Of Determining RevenuesMARKET VALUEMethodOfDeterminingRevenuesTxt

Food Inventory FoodInventoryGrp

FieldValueIRS element (for citing)
Non Cash CheckboxYes (X)NonCashCheckboxInd
Contribution70ContributionCnt

Drugs And Medical Supplies DrugsAndMedicalSuppliesGrp

FieldValueIRS element (for citing)
Non Cash CheckboxYes (X)NonCashCheckboxInd
Contribution6ContributionCnt
Noncash Contributions Rpt F990$3,442,425NoncashContributionsRptF990Amt
Method Of Determining RevenuesMARKET VALUEMethodOfDeterminingRevenuesTxt

Other Non Cash Contri Table OtherNonCashContriTableGrp (2 entries)

Non Cash CheckboxNonCashCheckboxIndDescDescContributionContributionCntNoncash Contributions Rpt F990NoncashContributionsRptF990Amt
Yes (X)PRINTED ITEMS7
Yes (X)VARIOUS129$109,820
FieldValueIRS element (for citing)
Any Property That Must Be HeldfalseAnyPropertyThatMustBeHeldInd
Review Process Unusual NC GiftsYes (true)ReviewProcessUnusualNCGiftsInd
Third Parties UsedfalseThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE M, PAGE 2, PART IIFormAndLineReferenceDesc
ExplanationPART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS. PART I, LINE 33 - EXPLANATION FOR NOT REPORTING REVENUE LLS ONLY RECORDS DONATED SECURITIES AS REVENUE. ALL OTHER ITEMS FOR WHICH COLUMN A IS CHECKED ARE NOT RECORDED AS REVENUE OR EXPENSE BECAUSE THEY WOULD NOT HAVE BEEN PURCHASED HAD THEY NOT BEEN DONATED, AND ARE IMMATERIAL IN AMOUNT RELATIVE TO THE STATEMENTS OF LLS.ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (16 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
FORM 990, PAGE 2, PART III, LINE 4AWE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2017, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 50 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, AND, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGAINST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2017, FOR THE SIXTH YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOLENT LYMPHOMA PATIENTS - DEFINE GENETIC/MOLECULAR PREDISPOSITIONS TO LONG-TERM AND LATE-TERM EFFECTS ASSOCIATED WITH STANDARD THERAPIES IN PEDIATRIC ALL AND APPLY THIS INFORMATION TO IMPROVE PATIENT OUTCOMES. THE THERAPY ACCELERATION PROGRAM THIS STRATEGIC INITIATIVE WAS LAUNCHED IN 2007 TO MOVE NEW TREATMENTS AND DIAGNOSTICS THROUGH PRECLINICAL DEVELOPMENT AND CLINICAL TRIALS, FASTER. USING MILESTONE-DRIVEN CONTRACTS AND WORKING IN CONCERT WITH ACADEMIC INVESTIGATORS, MEDICAL CENTERS AND COMPANIES, LLS IS FURTHER BRIDGING THE GAP BETWEEN DISCOVERY AND HUMAN APPLICATIONS TO INCREASE THE LIKELIHOOD THAT NOVEL, POSSIBLY BREAKTHROUGH, TREATMENTS WILL BE AVAILABLE TO PATIENTS AS SOON A
FORM 990, PAGE 2, PART III, LINE 4BSUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PRINT PUBLICATIONS AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES DISEASE AND SUPPORT BOOKLETS AND FACT SHEETS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. EACH YEAR, LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. - 632,829 FREE PRINTED DISEASE AND SUPPORT BOOKLETS AND 7,191 DISEASE- FOCUSED FACT SHEETS WERE ORDERED IN 2017. ADDITIONALLY, THERE WERE 86,615 PAGE VIEWS OF THESE BOOKLETS AND FACT SHEETS ON THE LLS WEBSITE. FINANCIAL ASSISTANCE IN 2017, A COMBINED 74,188,838 WAS DISBURSED TO PATIENTS THROUGH THE CO- PAY ASSISTANCE PROGRAMS (72,968,508) AND THE LLS NATIONAL PATIENT TRAVEL ASSISTANCE PROGRAM, (1,181,500), AND LLS FINANCIAL ASSISTANCE PROGRAM (38,830). CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2017, 72,968,508 WAS PROVIDED TO PATIENTS THROUGH THE LLS CO-PAY ASSISTANCE PROGRAM. - 31,026 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2017. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM THE SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS WITH TRAVEL AND LODGING EXPENSES RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. TRAVEL ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY. IN 2017, 1,181,500 WAS PROVIDED TO PATIENTS THROUGH THE LLS SUSAN LANG TRAVEL PROGRAM 2,363 PATIENTS RECEIVED LLS TRAVEL ASSISTANCE IN 2017. FINANCIAL ASSISTANCE PROGRAM FOR CML PATIENTS (PCR PROGRAM) THE FINANCIAL ASSISTANCE PROGRAM FOR CML PATIENTS SUPPORTS QUALIFYING PATIENTS WITH OUT OF POCKET EXPENSES RELATED TO THEIR ROUTINE POLYMERASE CHAIN REACTION (PCR) TESTING. IN 2017, 38,830 WAS PROVIDED TO PATIENTS THROUGH THE PCR PROGRAM. 85 PATIENTS RECEIVED LLS PCR ASSISTANCE IN 2017. COMMUNITY PROGRAMS SERVICES ARE PROVIDED IN COMMUNITIES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS BY PATIENT ACCESS STAFF AND TRAINED VOLUNTEERS WHO HAVE SPECIFIC SUPPORT AND OUTREACH ROLES. STAFF ARE HEALTHCARE AND ALLIED HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING, PUBLIC HEALTH OR SOCIAL WORK; VOLUNTEERS ARE TYPICALLY PATIENTS OR CAREGIVERS WHO UNDERGO RIGOROUS BACKGROUND CHECKS AND TRAINING. STAFF AND VOLUNTEERS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS, AND PROVIDE COMMUNITY-BASED OUTREACH, EDUCATION, AND SUPPORT IN A VARIETY OF FORMS. REGIONAL BLOOD CANCER CONFERENCES: LLS WORKS TO ELEVATE OUR VISIBILITY IN COMMUNITIES WE SERVE BY HOSTING LARGER-SCALE CONFERENCES, GEARED FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. THESE EVENTS ARE A CATALYST FOR BRINGING MANY DEDICATED PEOPLE TOGETHER TO FOCUS ON BLOOD CANCER AWARENESS, INFORMATION AND THE LATEST ADVANCES IN MEDICAL SCIENCE. THEY ARE DESIGNED FOR PATIENTS AND CAREGIVERS BUT ARE ATTENDED BY SOME LOCAL HEALTHCARE PROFESSIONALS (NURSES AND SOCIAL WORKERS) AS WELL. IN 2017, 106 BCC CONFERENCES WERE HELD WITH 3,352 ATTENDEES. LLS COMMUNITY THE ONLINE "LLS COMMUNITY" WAS LAUNCHED ON FEBRUARY 1, 2016. IT WAS DESIGNED TO PROVIDE A WAY FOR PATIENTS AND CAREGIVERS TO: 1) BECOME PART OF A SOCIAL NETWORK TO CONNECT WITH PATIENTS AND CAREGIVERS IN SIMILAR SITUATIONS AND BECOME EMPOWERED; 2) PROVIDE INFORMATION ABOUT ONESELF AND ONE'S DISEASE, TO BECOME PART OF THE RESEARCH TO CURE BLOOD CANCERS; AND 3) GAIN THE LATEST INFORMATION ABOUT ONE'S DISEASE, LEARN ABOUT SURVIVORSHIP ISSUES, AND ABOUT CLINICAL TRIALS. BY THE END OF FY 2017, THERE WERE APPROXIMATELY 6,000 COMMUNITY MEMBERS AND 44,000 RESPONSES TO THE "QUESTIONS OF THE DAY," AS WELL AS CLOSE TO 13,500 COMMENTS POSTED BY USERS. FAMILY SUPPORT GROUPS: THROUGHOUT THE US, IN 2017, LLS SUPPORTED OR HOSTED 135 FAMILY SUPPORT GROUPS FOR PATIENTS AND THEIR FAMILIES. GROUPS ARE GUIDED BY ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. LLS SUPPORT GROUPS ARE THE PERFECT PLACE TO TALK WITH OTHER PEOPLE AFFECTED BY BLOOD CANCERS, INCLUDING PATIENTS, FAMILY MEMBERS AND CAREGIVERS. THE GROUPS PROVIDE MUTUAL SUPPORT AND OFFER THE OPPORTUNITY TO DISCUSS ANXIETIES AND CONCERNS WITH OTHERS WHO SHARE THE SAME EXPERIENCES. THIS SHARING STRENGTHENS THE FAMILY BOND AND ENHANCES EVERYONE'S ABILITY TO COPE WITH CANCER. IN ADDITION, LLS HOSTED 7 ONLINE CHAT GROUPS - I.E., VIRTUAL SUPPORT GROUPS - THAT ARE PROFESSIONALLY MODERATED. IN FY 2017, 3,506 INDIVIDUALS PARTICIPATED IN THESE CHATS. PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM: FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT- VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS; REFERRAL IS ALSO PROVIDED BY LLS'S INFORMATION RESOURCE CENTER. -OVER 1,100 FIRST CONNECTIONS WERE MADE ACROSS THE US IN FY 2017.
FORM 990, PAGE 2, PART III, LINE 4CINFORMATION SPECIALISTS ALSO CONDUCT CLINICAL-TRIAL SEARCHES TO HELP PATIENTS WORK WITH THEIR DOCTORS TO FIND OUT ABOUT SPECIFIC CLINICAL TRIALS. THE INFORMATION RESOURCE CENTER ALSO HAS AN EXPANDING IN-DEPTH CLINICAL TRIAL NAVIGATION SERVICE. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. IN FY 2017: - 17,800 INQUIRIES WERE MADE TO OUR INFORMATION SPECIALISTS. - 10,632 HOUSEHOLDS RECEIVED INFORMATION AND/OR SUPPORT FROM INFORMATION SPECIALISTS VIA EMAILS, PHONE, AND ANSWER CHATS. -339 PATIENTS WORKED WITH A CLINICAL TRIAL NAVIGATOR TO RECEIVE COMPREHENSIVE ASSISTANCE WITH CLINICAL TRIAL ENROLLMENT; OVER 60% OF THESE PATIENTS ENROLLED ON A CLINICAL TRIAL. THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, DISCUSSION BOARDS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL- TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. INFORMATIONAL MATERIALS ARE AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. MANY DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS ADDITIONALLY, LLS ALSO SPONSORS TELEPHONE- WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. ALSO AVAILABLE THROUGH THE LLS WEBSITE ARE VIRTUAL LECTURES AND VIDEOS FEATURING DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. IN FY 2017: -LLS PROVIDED 10 LIVE NATIONAL TELEPHONE-WEB EDUCATION PROGRAMS, WITH 4,605 PARTICIPANTS -THERE WERE 21,766 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, 29,453 VIEWS OF VIDEOS.
FORM 990, PAGE 2, PART III, LINE 4DD) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. IN FY 2017: -LLS PROVIDED 5 CME/CE-GRANTING PERSON EDUCATIONAL PROGRAMS ("ROUNDS"), WITH 1,468 HEALTHCARE PROFESSIONAL IN ATTENDANCE. -THERE WAS 1 NATIONAL TELEPHONE-WEB EDUCATION PROGRAM FOCUSED ON AML FOR PROFESSIONALS WITH 479 PARTICIPANTS. -THERE WERE 9,656 VIEWS OF OUR ONLINE VIRTUAL LECTURES FOR PROFESSIONALS AND 2,904 VIEWS OF OUR ONLINE VIDEOS FOR PROFESSIONALS.
FORM 990, PART V, LINE 4BCANADA
FORM 990, PAGE 6, PART VI, LINE 6THE MEMBERS OF LLS CONSIST OF ONE ELECTED REPRESENTATIVE FROM EACH CHAPTER.
FORM 990, PAGE 6, PART VI, LINE 7ATHE BOARD OF REPRESENTATIVES (REPRESENTING THE CHAPTERS) ELECTS THE MEMBERS OF LLS'S GOVERNING BODY, ITS NATIONAL BOARD OF DIRECTORS.
FORM 990, PAGE 6, PART VI, LINE 7BSIGNIFICANT DECISIONS AFFECTING THE CHAPTERS REQUIRE AN APPROVING VOTE BY THE CHAPTER DELEGATES. DECISIONS NOT SIGNIFICANTLY AFFECTING THE CHAPTERS DO NOT REQUIRE APPROVAL FROM THE CHAPTER DELEGATES.
FORM 990, PAGE 6, PART VI, LINE 11BTHE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CFO, SR. VICE PRESIDENT OF FINANCE, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990, AS WILL BE FILED WITH THE IRS, WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING WITH THE IRS.
FORM 990, PAGE 6, PART VI, LINE 12CALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES MEMBERS, CHAPTER BOARD MEMBERS, FAMILY SUPPORT GROUP FACILITATORS, AND TNT COACHES ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL FORMS ARE COLLECTED AND THE AUDIT COMMITTEE REVIEWS ANY FORMS DISCLOSING A POSSIBLE CONFLICT OF INTEREST AND DETERMINES WHETHER OR NOT A CONFLICT EXISTS. PART VI, LINE 12 C: ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES ARE RECUSED FROM ANY DISCUSSION WHERE A CONFLICT OF INTEREST EXISTS. ANY QUESTIONS REGARDING COI WILL GO TO THE AUDIT COMMITTEE.
FORM 990, PAGE 6, PART VI, LINE 15ATHE EXECUTIVE COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS, MONITORS, AND APPROVES THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. IN 2017 THE EXECUTIVE COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THEIR COMPENSATION MARKET LEVELS AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET, APPROVED AND DOCUMENTED THE PROCESS IN THE COMMITTEE MINUTES.
FORM 990, PAGE 6, PART VI, LINE 15BIN 2017, THE EXECUTIVE COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THE COMPENSATION MARKET LEVELS OF OTHER OFFICERS AND KEY EMPLOYEES AND TO APPROVE THE PRESIDENT AND CEO'S RECOMMENDATIONS ON THEIR COMPENSATION LEVELS.
FORM 990, PAGE 6, PART VI, LINE 17ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA
FORM 990, PAGE 6, PART VI, LINE 19THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990.
FORM 990, PART VIIIIN JANUARY 2009, AS PART OF ITS THERAPY ACCELERATION PROGRAM (TAP), LLS ENTERED INTO AN AGREEMENT WITH CELATOR PHARMACEUTICALS, INC. (CELATOR) THROUGH WHICH LLS PROVIDED FUNDING OF APPROXIMATELY 4.1M TO CELATOR IN SUPPORT OF THE PHASE 2 STUDY OF CELATOR'S LEAD COMPOUND VYXEOS (DAUNORUBICIN AND CYTARABINE LIPOSOME FOR INJECTION) FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML). FROM 2012 THROUGH 2016, LLS PROVIDED FUNDING OF AN ADDITIONAL 5.0M FOR THE PHASE 3 CLINICAL STUDY OF VYXEOS. LLS PROVISIONS OF FUNDING TO CELATOR WERE BASED ON CLINICAL MILESTONES. AS PART OF THE AGREEMENT, CELATOR WAS OBLIGATED TO MAKE PAYMENTS TO LLS RELATIVE TO THE TIMING OF THE PRODUCT COMMERCIALIZATION AND OTHER LIQUIDITY EVENTS. IN JULY 2016, JAZZ PHARMACEUTICALS (JAZZ) COMPLETED THE PURCHASE OF CELATOR, TRIGGERING A PAYMENT OF 13.7M TO LLS. IN LATE 2016, JAZZ TERMINATED THE AGREEMENT WITH LLS TRIGGERING A ONE TIME CONTRACT TERMINATION FEE OF 11.6M TO ELIMINATE POTENTIAL FUTURE ROYALTY PAYMENTS RELATED TO VYXEOS. THE TOTAL AMOUNT OF THE RETURN TO LLS FROM ITS TAP INVESTMENT IN CELATOR WAS 25.3M. THE REMAINING 4.2M OF TAP CONTRACTUAL RETURN COMES FROM VARIOUS OTHER TAP INVESTMENTS
FORM 990, PART XI, LINE 9LLS CANADA RESTATEMENT -268,729 FINANCIAL STATEMENT ROUNDING 589 TOTAL -268,140

Schedule R IRS990ScheduleR

Id Disregarded Entities IdDisregardedEntitiesGrp

Disregarded Entity Name DisregardedEntityName

FieldValueIRS element (for citing)
Business Name Line1BEAT AML LLCBusinessNameLine1Txt

US Address USAddress

FieldValueIRS element (for citing)
Address Line13 INTERNATIONAL DRIVEAddressLine1Txt
CityRYE BROKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10573ZIPCd
FieldValueIRS element (for citing)
Primary ActivitiesRESEARCHPrimaryActivitiesTxt
Legal Domicile StateNYLegalDomicileStateCd
Total Income$3,847,455TotalIncomeAmt
End Of Year Assets$9,407,419EndOfYearAssetsAmt

Direct Controlling Entity Name DirectControllingEntityName

FieldValueIRS element (for citing)
Business Name Line1LLSBusinessNameLine1Txt

Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (4 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdEINEINPrimary ActivitiesPrimaryActivitiesTxtLegal Domicile StateLegalDomicileStateCdExempt Code SectionExemptCodeSectionTxtPublic Charity StatusPublicCharityStatusTxtBusiness Name Line1DirectControllingEntityName/BusinessNameLine1TxtControlled OrganizationControlledOrganizationIndAddress Line1ForeignAddress/AddressLine1TxtCityForeignAddress/CityNmCountryForeignAddress/CountryCdForeign PostalForeignAddress/ForeignPostalCdLegal Domicile Foreign CountryLegalDomicileForeignCountryCd
THE LLS RESEARCH PROGRAMS INC
3 INTERNATIONAL DRIVERYE BROOKNY10573133470494PART VIIDE501C312ALLS INCYes (true)
THE LLS RESEARCH FOUNDATION
3 INTERNATIONAL DRIVERYE BROOKNY10573133709252PART VIIDE501C312ALLS INCYes (true)
THE LLS OF CANADA
PART VIINAfalse804 2 LANSING SQUARETORONTOCAM2J4P8CA
PEARLPOINT CANCER SUPPORT
2817 WEST END AVENUENASHVILLETN37203581747771PART VIITN501C37LLS INCYes (true)
FieldValueIRS element (for citing)
Receipt Of Int Annts Rnts RyltsfalseReceiptOfIntAnntsRntsRyltsInd
Gift Grnt Or Cap Contri To Oth OrgYes (true)GiftGrntOrCapContriToOthOrgInd
Gift Grnt Cap Contri From Oth OrgYes (true)GiftGrntCapContriFromOthOrgInd
Loans Or Guarantees To Other OrgfalseLoansOrGuaranteesToOtherOrgInd
Loans Or Guarantees From Oth OrgfalseLoansOrGuaranteesFromOthOrgInd
Div Related OrganizationfalseDivRelatedOrganizationInd
Asset Sale To Other OrgfalseAssetSaleToOtherOrgInd
Asset Purchase From Other OrgfalseAssetPurchaseFromOtherOrgInd
Asset ExchangefalseAssetExchangeInd
Rental Of Facilities To Oth OrgfalseRentalOfFacilitiesToOthOrgInd
Rental Of Fclts From Oth OrgfalseRentalOfFcltsFromOthOrgInd
Perform Of Services For Oth OrgYes (true)PerformOfServicesForOthOrgInd
Perform Of Services By Other OrgfalsePerformOfServicesByOtherOrgInd
Sharing Of FacilitiesYes (true)SharingOfFacilitiesInd
Paid Employees SharingYes (true)PaidEmployeesSharingInd
Reimbursement Paid To Other OrgfalseReimbursementPaidToOtherOrgInd
Reimbursement Paid By Other OrgYes (true)ReimbursementPaidByOtherOrgInd
Transfer To Other OrgfalseTransferToOtherOrgInd
Transfer From Other OrgfalseTransferFromOtherOrgInd

Transactions Related Org TransactionsRelatedOrgGrp (3 entries)

Transaction TypeTransactionTypeTxtInvolvedInvolvedAmtMethod Of Amount DeterminationMethodOfAmountDeterminationTxt
THE LLS OF CANADA
B$4,194,727COST
THE LLS OF CANADA
C$77,724COST
PEARLPOINT CANCER SUPPORT
L$118,848COST

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE RFormAndLineReferenceDesc
ExplanationTHE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA & LYMPHOMA SOCIETY, INC., IN CANADA. THE LEUKEMIA SOCIETY RESEARCH PROGRAMS, INC. AND THE LEUKEMIA RESEARCH FOUNDATION, INC. SUPPORT THE ACTIVITIES OF THE LEUKEMIA & LYMPHOMA SOCIETY, INC. THE LEUKEMIA & LYMPHOMA SOCIETY, INC. IS THE 100% CONTROLLING MEMBER OF PEARLPOINT CANCER SUPPORT, INC.ExplanationTxt

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.